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The aim of this thesis was to investigate the effects of transcranial direct current stimulation 
(tDCS) as a memory enhancer in Alzheimer’s disease patients and healthy individuals. In 
addition, we wanted to study how verbal memory functions are related to hippocampus 
subfield volumes.  
This thesis consists of three reports, in which two of the reports (I and II) aimed to study the 
effects of tDCS, and the other report (III) focused on verbal memory and subfields of the 
hippocampus. In all three reports, the California Verbal Learning Test II (CVLT-II) was used 
to assess verbal memory functions. The CVLT-II is normed for age and sex and is a widely 
used memory test, in both experimental and clinical settings.  
In reports I and II, the effect of a stimulation method called “transcranial direct current 
stimulation (tDCS)” was investigated. This is a noninvasive method in which two or more 
electrodes are placed on the scalp. The electrode positioning depends on the area intended to 
be stimulated. A weak direct current is delivered through the scalp and aims to increase 
cortical excitability (i.e., aims to make the neurons more capable of responding to stimuli). 
The stimulation electrode (the anode) was placed over the temporal cortex, whereas the 
reference electrode (the cathode) was placed over the right frontal cortex.   
In report I, we used a randomized controlled trial design in which 26 patients with 
Alzheimer’s disease underwent six 30-minute sessions of tDCS stimulation during a two-
week period. Half of them received active tDCS stimulation, while the other half received 
placebo tDCS. We found no significant differences between active and placebo tDCS, neither 
in the primary outcome nor in the secondary outcome measures.  
In report II, 40 healthy participants underwent six tDCS sessions for two consecutive days. 




significant differences were found in verbal memory outcomes. However, in the young 
participants there was a significant difference between active and placebo tDCS in executive 
functions measured by the Trail Making Test, part B (TMT B).  
In report II, we investigated the relation between verbal memory and hippocampal subfield 
volumes in 47 right-handed healthy adults. T1-weighted MRI results were obtained using a 
1,5 Tesla scanner. The results showed a significant correlation between left hippocampal 
subfields volumes and verbal memory. However, no significant correlations were found 
between right hippocampal volumes and verbal memory.  
The overall conclusions are as follows: 1) In patients with Alzheimer’s disease, six 30-minute 
sessions of active tDCS over a period of two weeks did not offer any significant 
improvements in memory functions, compared to the placebo tDCS results. However, the 
generalizability is limited due to the small sample size. 2) In healthy participants, six 30-
minute sessions of active tDCS for two consecutive days did not offer significantly better 
memory outcomes, compared to the placebo tDCS results. 3) In healthy adults, there was a 













Hensikten med denne avhandlingen var å undersøke om transcranial Direct Current 
Stimulation (tDCS) kan bedre verbale hukommelsesfunksjoner hos pasienter med Alzheimers 
sykdom og friske deltakere, samt å undersøke sammenhengen mellom verbal hukommelse og 
volum av hippocampus og sub-strukturer av hippocampus.  
Avhandingen består at tre artikler, der to av artiklene (I og II) undersøkte effektene av tDCS, 
mens den siste artikkelen (III) studerte verbal hukommelse og hippocampus volum. I alle tre 
artiklene ble California Verbal Learning Test II (CVLT-II) brukt som mål på verbal 
hukommelsesfunksjon. CVLT-II er en nevropsykologisk test som er normert for både alder og 
kjønn og er mye brukt i forskning og klinikk.  
I artikkel I og II ble effekten av tDCS undersøkt. Dette er en ikke-invasiv metode der to eller 
flere elektroder plasseres i hodebunnen, over det området man ønsker å stimulere. En svak 
likestrøm går gjennom hodeskallen og har til hensikt å påvirke kortikal eksitabilitet (dvs. at 
nevronene reagerer lettere på stimuli). Stimuleringselektroden (anoden) ble plassert over 
venstre temporal korteks, mens referanse elektroden (katoden) ble plassert over høyre frontal 
korteks.  
I artikkel I brukte vi et randomisert kontrollert design der 26 pasienter med Alzheimers 
sykdom fikk seks behandlingssesjoner med tDCS i løpet av to uker. Varigheten på hver sesjon 
var 30 minutter. Halvparten av pasientene fikk aktiv tDCS, mens den andre halvparten fikk 
placebo tDCS. Vi fant ingen signifikant forskjell mellom aktiv og placebo tDCS, hverken på 
primære eller sekundære utfallsmål.  
I artikkel II fikk 40 friske deltakere seks sesjoner med tDCS, fordelt på to påfølgende dager. 




ikke funnet noen signifikant forskjell i verbal hukommelsesfunksjon, men det var en 
signifikant forskjell mellom aktiv og placebo tDCS i eksekutiv funksjon hos de yngre 
deltakerne, målt med Trail Making Test B (TMT-B).  
I artikkel II undersøkte vi sammenhengen mellom verbal hukommelsesfunksjon og 
hippocampus volum hos 47 høyrehendte voksne deltakere. En MR scanner med 1,5 tesla ble 
benyttet. Resultatene viste en signifikant korrelasjon mellom venstre hippocampus volum og 
verbal hukommelse, mens det derimot ikke var noen signifikant korrelasjon mellom høyre 
hippocampus volum og verbal hukommelse.  
Konklusjonene fra de tre rapportene var følgende: 1) Hos pasienter med Alzheimers sykdom 
gir ikke seks 30 minutters seksjoner med aktiv tDCS i løpet av to uker noen signifikant 
forbedring i hukommelsesfunksjon, sammenliknet med placebo tDCS. Det var imidlertid få 
deltakere, noe om begrenser generaliserbarheten 2) Hos friske deltakere ga ikke seks sesjoner 
med 30 minutter aktiv tDCS over to påfølgende dager noen signifikant forbedring i 
hukommelsen, sammenliknet med placebo tDCS 3) Hos friske deltakerne var det en 










Transcranial direct current stimulation as a memory enhancer in healthy participants 
and patients with Alzheimer’s disease  
 
Introduction  
The idea that electrical currents may affect our brain has persisted for two thousand years. 
Roman physician Scribonius Largus claimed that placing an electrical torpedo fish over the 
scalp could reduce headaches (Sarmiento, San-Juan, & Prasath, 2016). One of the first trials 
with electrical current treatment methods for melancholia was conducted in the middle of the 
18th century (Sarmiento et al., 2016). However, during the 19th century, there was an increasing 
interest in investigating the possible electrical current treatment methods for mental disorders.
 A method that gained ground during the last 20 years is transcranial direct current 
stimulation, abbreviated “tDCS”. The application of tDCS is noninvasive, associated with few 
adverse effects, simple to use and inexpensive (Nitsche & Paulus, 2011). The current is a low 
direct current, usually as low as 1-2 mA, delivered through electrodes placed on the scalp 
(Nitsche & Paulus, 2011).          
 tDCS must never be confused with “electroconvulsive therapy” (ECT). The latter 
involves anesthesia, and the current used is far stronger and leads to seizures (Higgins & 
George, 2009). While ECT is primarily used in psychiatric hospitals as a treatment method for 
severe depression, tDCS has a broader area of application. The applications of tDCS range from 
the treatment of chronic pain (Fagerlund, Hansen, & Aslaksen, 2015) to enhancing cognitive 
functions in healthy individuals (Chi, Fregni, & Snyder, 2010). Patients can even administer 
tDCS treatment themselves with preprogrammed devices optimized for this purpose. This broad 
application, combined with few adverse effects (mainly redness, itching and tingling), may have 
led to an increased use of and interest in tDCS (Brunoni et al., 2011).    




electrical current through a coil that leads to a magnetic field. This magnetic field is delivered 
across the skull and alters neuronal activity (Priori, Hallett, & Rothwell, 2009). While tDCS 
relies on a weak direct current, TMS relies on a magnetic field (Priori et al., 2009). Both TMS 
and tDCS aim to change cortical excitability (i.e., make the neurons more capable of responding 
to stimuli) (Fregni & Pascual-Leone, 2007). tDCS is better suited for double blind studies than 
TMS. This suitability is as such because tDCS leads to minimal scalp sensations, while TMS 
may lead to strong scalp sensations, and it is challenging to induce such scalp sensations for 
placebo TMS (Priori et al., 2009).        
 Most tDCS studies use either “anodal” stimulation or “cathodal” stimulation. The 
difference between these two stimulation methods is the polarity. Anodal stimulation induces 
excitatory effects, while cathodal stimulation decreases excitatory effects (DaSilva, Volz, 
Bikson, & Fregni, 2011). Usually, the anode is referred to as the “stimulation electrode”, 
whereas the cathode is referred to as the “reference electrode”. The reports in this thesis used 
anodal stimulation, i.e., the anodal electrode was placed above the brain area to be stimulated.
 It is estimated that approximately 50% of the current enters the cortex through the skull,  
in both humans and monkeys (Nitsche, Kuo, Paulus, & Antal, 2015). Undeniably, some of the 
current will not reach the cortex because of the skull, cerebrospinal fluid, blood, etc. One study 
(Underwood, 2016) claimed that only 10 % of the current reached the tissue. However, this 
result was obtained in a cadaver with dead brain tissue, making a comparison to living tissue 
difficult.           
 Electrode positioning can be important for the efficacy of tDCS stimulation. Both 
computational modeling studies and studies monitoring physiological changes from tDCS 
stimulation suggest that positioning can affect stimulation efficacy (Woods et al., 2016). In 
general, the stimulation electrode should be placed on the scalp above the cortical area to be 




above the frontal lobe may be most appropriate for depression due to the assumption that 
depression is associated with hypoactivation of the frontal lobes (Palm, Hasan, Strube, & 
Padberg, 2016).          
 Most studies use a current strength of 1-2 mA (Bikson, Datta, & Elwassif, 2009). Some 
studies have investigated the effect of 4 mA (Chhatbar et al., 2017). However, for safety 
reasons, it is recommended to not exceed 2 mA (Iyer et al., 2005). Reports (I and II) in this 
thesis applied a current strength of 2 mA. 
Neuroplasticity and the mechanisms of tDCS 
The brain has a remarkable ability for adaptability and changing itself (Doidge, 2007). The 
prefix neuro refers to the “neuron” (the nerve cells in our brain), while the suffix plasticity 
means changeable, malleable and modifiable (Doidge, 2007). Learning and memory rely on 
neuroplasticity (Petrovic et al., 2017).        
 Neuroplasticity can be observed throughout the life span. For instance, Envig and 
colleagues (Engvig et al., 2010) investigated the effect of memory systems (mnemonics) in 
healthy elderly individuals. They found that specific memory systems/strategies may improve 
memory functions. Even more interestingly, they used magnetic resonance imaging and found 
that eight weeks of such memory training increased cortical thickness.     
 Such neuroplasticity was also found in a study by Maguire and colleagues (Maguire, 
Woollett, & Spiers, 2006). They investigated London taxi drivers by using neuroimaging. 
They revealed that these taxi drivers had greater posterior hippocampal volume compared to 
that of controls. It is reasonable to believe that such hippocampal volume was a result of their 
need to navigate and remember a huge number of routes. Furthermore, physical activity may 
enhance neuroplasticity (Hillman, Erickson, & Kramer, 2008). This enhancement was also 
demonstrated in a study in which elderly individuals began aerobic exercise (Erickson et al., 




memory and neuroplasticity. At the one-year follow-up, it was found that participants in the 
aerobic exercise group had increased hippocampal volume by two percent, whereas 
hippocampal volume declined in the stretching group.     
 The potential for neuroplasticity seems to decrease with aging (Barnes, 2003; Rossini, 
Ferilli, Rossini, & Ferreri, 2013). Such a decrease in neuroplasticity may explain why older 
individuals experience more memory deficits than younger individuals do (Barnes, 2003). 
Furthermore, Alzheimer’s disease leads to inhibited neuroplasticity (Kumar et al., 2017). To 
improve memory functions in healthy individuals and patients with brain disorders, it is 
reasonable to assume that enhancing neuroplasticity could be useful.     
 Long-term potentiation (LTP) is crucial for neuroplasticity. LTP is a long-term 
increase in the excitability of neurons with respect to particular synaptic inputs caused by the 
repeated high frequency of that input (Carlson, 2013). LTP involves a long-term increase in 
synaptic strength (Bliss & Collingridge, 1993). This increase builds on the principle of “fire 
together, wire together” and was demonstrated experimentally by Lømo several decades ago 
(Carlson, 2013). A large number of studies have revealed that LTP involves an increase in the 
number of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the 
postsynaptic membrane (Carlson, 2013). Having more AMPA receptors leads to more 
glutamate being bound, thus causing a larger excitatory postsynaptic potential (Henley & 
Wilkinson, 2016). It is also assumed that LTP can be elicited by the activation of N-methyl-
D-aspartate (NMDA) glutamate receptors (Lüscher & Malenka, 2012). We now know that 
LTP forms the basis for neuroplasticity and for learning and memory (Petrovic et al., 2017). 
 The opposite of LTP is long-term depression (LTD). LTD is a long-term decrease in 
the excitability of a neuron with respect to a particular synaptic input caused by terminal 
bouton stimulation, while the postsynaptic membrane is hyperpolarized or only slightly 




reduction in AMPA receptors (Henley & Wilkinson, 2016).     
 In the field of neuroplasticity, brain-derived neurotrophic factor (BDNF) has gained 
ground (Tapia-Arancibia, Aliaga, Silhol, & Arancibia, 2008). BDNF is a neurotrophic factor 
and helps support the growth and survival of neurons (Cunha, Brambilla, & Thomas, 2010). 
BDNF promotes LTP (Cunha et al., 2010). Both aging and Alzheimer’s disease are associated 
with lower levels of BDNF (Tapia-Arancibia et al., 2008).     
 The main mechanism of tDCS is to trigger neurons to stimulate or form new 
connections (Giordano et al., 2017). tDCS aims to alter the resting state potential of neurons 
and thereby induce neuroplasticity (Stagg & Nitsche, 2011). More specifically, tDCS 
facilitates neural function by modulating cortical excitability (Stagg & Nitsche, 2011). It is 
important to emphasize that tDCS does not directly cause neuronal firing but triggers 
conditions that make neuronal firing more likely (Reinhart, Cosman, Fukuda, & Woodman, 
2017).            
 Studies using functional magnetic resonance imaging (fMRI), electroencephalography 
(EEG) and pharmacological approaches suggest that tDCS leads to neurophysiological 
changes in the cortex (Venkatakrishnan & Sandrini, 2012). For instance, Keeser applied EEG 
(Keeser, Padberg, et al., 2011) and fMRI (Keeser, Meindl, et al., 2011) and revealed that 
tDCS stimulation can increase excitability and strengthen connectivity within different resting 
state networks. Additionally, neuroimaging studies have found that during tDCS stimulation, 
regional cerebral blood flow increases by 17% (Zheng, Alsop, & Schlaug, 2011). 
 Madeiros and colleagues (Medeiros et al., 2012) suggested that tDCS alters the levels 
of neurotransmitters underneath the electrode. It has been found that a single tDCS session 
increases the levels of glutamate, which is the primary excitatory neurotransmitter (Hone-
Blanchet, Edden, & Fecteau, 2016). Glutamate plays an important role in LTP (Granger, Shi, 




acid (GABA), a neurotransmitter with inhibitory effects (Bachtiar, Near, Johansen-Berg, & 
Stagg, 2015; Stagg et al., 2009). In addition, citalopram (a selective serotonin reuptake 
inhibitor) can prolong the effects of tDCS stimulation of the motor cortex (Nitsche et al., 
2009). Furthermore, tDCS also increases the concentrations of calcium (CA2+) and BDNF, 
which play important roles in neuroplasticity (Das, Holland, Frens, & Donchin, 2016).  
 The excitatory effects of tDCS stimulation persist after the stimulation ends (Nitsche 
& Paulus, 2001; Podda et al., 2016). Stimulation for nine minutes may elicit excitatory effects 
after 30 minutes, whereas 13-minute stimulations lead to alterations that last for up to 90 
minutes (Thair, Holloway, Newport, & Smith, 2017). It could be reasonable to assume that 
longer stimulations will increase the duration of the after-effects compared to the duration 
induced by shorter stimulations. However, Monte-Silva and colleagues (Monte-Silva et al., 
2013) revealed that tDCS sessions for longer than 26 minutes may lead to inhibitory effects 
rather than excitatory effects. This outcome may result from a calcium overflow that impairs 
neuroplasticity (Monte-Silva et al., 2013). In sum, the optimal duration of tDCS stimulation is 
still uncertain.           
 Despite the fact that tDCS has been studied extensively, relatively few studies have 
investigated the exact physiological mechanisms behind tDCS. Thus, the underlying 
mechanisms of tDCS are not fully understood (Bennabi et al., 2014; Mohammadi, 2016). 
Moreover, most mechanistic studies on the physiological effects of tDCS have focused on the 
motor cortex. This focus is highly relevant for stroke patients if the stroke is located in the 
motor complex but less relevant for other functions, e.g., memory functions (Medeiros et al., 
2012). 
tDCS is a cognitive enhancer in healthy participants      
 As a cognitive enhancer, tDCS has gained interest. Improving cognitive abilities has 




passively for millions of years before evolution offers him a better brain.” (Farah, 2015).
 There is evidence that tDCS may improve cognitive functions in healthy people, i.e.,  
verbal fluency, working memory, verbal episodic memory, visual memory, attention and 
language processing speed (Tremblay et al., 2014). For instance, Ross and colleagues found 
that tDCS could enhance name recall in both younger and elderly participants (Ross, McCoy, 
Coslett, Olson & Wolk, 2011). Likewise, another study found that tDCS could improve verbal 
memory in older and younger participants (Manenti, Brambilla, Petesi, Ferrari, & Cotelli, 
2013).             
 A recent meta-analysis investigated 24 tDCS studies, with a total of 566 participants 
above 60 years of age. They concluded that tDCS may ameliorate episodic memory in both 
healthy and cognitively impaired older adults (Huo et al., 2019). Despite the evidence that 
tDCS can improve cognitive functions, it should be emphasized that the results are mixed 
(Tremblay et al., 2014). Over the past two decades, over 3000 articles have investigated the 
effect of tDCS on different brain functions. Nevertheless, the studies investigating the effect 
of tDCS on cognition rely on different tDCS protocols, and the results are inconsistent. 
 In addition, most studies rely on a single session of stimulation (Horvath, Forte, & 
Carter, 2015). Consequently, this approach may limit the physiological effects. Since the 
after-effects of a single tDCS session are relatively short lived (60-90 minutes), it is important 
to rely on multiple sessions (Nitsche et al., 2015). To enhance cognitive function in daily life, 
the effect must last longer than the experimental session. Horvath and colleagues (Horvath et 
al., 2015) conducted a review and concluded that single tDCS sessions had minimal cognitive 
effects in healthy participants. They also concluded that multiple sessions may generate better 
effects.           
 Extending the duration of the tDCS sessions (longer than 30 minutes) does not seem to 




stimulations and a small interval between each stimulation is recommended (Nitsche et al., 
2015; Woods et al., 2016). Repeating the tDCS stimulation within a time window of 30 
minutes may lead to more cumulative effects (Nitsche et al., 2015). Nitsche and colleagues 
(Nitsche et al., 2015) suggest “simply prolonging stimulation duration seems not to be the 
optimal strategy. The alternative might be the repetition of stimulation sessions” (p. 102). 
Based on this recommendation, in report II, we used a novel stimulation protocol with short 
intervals between each tDCS session. There is clearly a need for better standardization among 
tDCS protocols in healthy participants (Tremblay et al., 2014). In addition, the optimal tDCS 
protocol for healthy participants needs to be further investigated. We still do not know 
whether short intervals (as we investigated in report II) are better than long intervals between 
tDCS sessions.          
 Normal aging is associated with a steady decline in cognitive function, especially 
memory functions (Ward, Berry, & Shanks, 2013). As the older population continues to grow, 
methods to reduce age-associated cognitive decline have gained increasing interest (Hsu, Ku, 
Zanto, & Gazzaley, 2015). Thus, in report II in this thesis, tDCS was investigated as a 
memory enhancer in both young and elderly participants. 
tDCS is a cognitive enhancer in Alzheimer’s disease     
 Alzheimer’s disease is a degenerative disease and the most common type of dementia, 
accounting for 60% of all cases of dementia (Blennow, de Leon, & Zetterberg, 2006). Due to 
increased life expectancy, it is estimated that the prevalence of Alzheimer’s disease will 
double during the next 30 years (Alzheimer`s Association, 2019). The prevalence of 
Alzheimer’s disease is less than one percent in people under 65 years of age, but for people 
over 85 years, the prevalence is between 24 and 33% (Blennow et al. 2006).   
 Alzheimer’s disease leads to a progressive decline in cognitive domains. This decline 




functions, visuospatial abilities and verbal abilities (Alzheimer`s Association, 2019; Mayeux, 
2010). Memory impairment is a core symptom of Alzheimer’s disease. One meta-analysis 
found memory decline to be the most pronounced symptom of Alzheimer’s disease 
(Bäckman, Jones, Berger, Laukka, & Small, 2005), especially in the “mild stage”.  
 The progressive decline in Alzheimer’s disease can broadly be defined by three stages: 
“mild Alzheimer’s disease”, “moderate Alzheimer’s disease” and “severe Alzheimer’s 
disease” (Henderson & Jorm, 2000). In the mild stage, or “early stage”, individuals 
experience difficulties acquiring new information and memory loss for recent events (for 
instance, an inability to remember what happened yesterday). In the moderate stage, memory 
loss may be more serious, and new information is immediately lost, but previous knowledge 
can be retained (for instance, remembering children’s names). In this stage, the declarative 
memory is profoundly affected, while the procedural memory is more intact. In the severe 
stage, the memory loss is monumental, and only fragments of the memory are left (for 
instance, remembering some events from childhood). In this stage, verbal function is usually 
very impaired. This impairment means that both the ability to understand and to produce 
words or sentences are severely affected. The life expectancy after diagnosis is estimated to 
be seven–ten years in many studies (Zanetti, Solerte, & Cantoni, 2009).     
 The exact cause and pathological mechanisms behind Alzheimer’s disease are 
uncertain. A common hypothesis is that Alzheimer’s disease leads to a massive loss of 
neurons as a consequence of excessive levels of plaques (beta-amyloid) and tangles (tau-
proteins) in the brain (Alzheimer`s Association, 2019; Mayeux, 2010). In the early stages of 
Alzheimer’s disease, these pathological changes are especially prominent in the medial 
temporal lobe, including the hippocampus and entorhinal cortex (Jack et al., 1997). Previous 
studies also suggest that Alzheimer’s disease is associated with decreased acetylcholine and 




neuroinflammation in the hippocampus (Valero et al., 2017). Hence, it seems likely that 
inflammatory processes are related to the pathology of Alzheimer’s disease (Frozza, 
Lourenco, & De Felice, 2018).        
 Since Alzheimer’s disease is highly complex, it remains extremely difficult to find a 
cure (Cummings, Morstorf, & Zhong, 2014). For instance, Cummings and colleagues 
(Cummings et al., 2014) reviewed clinical trials from 2002–2012 and found that the failure 
rate for drug development in Alzheimer’s disease is 99,6 %. There are few treatment options 
for patients with Alzheimer’s disease (Alzheimer’s Association, 2017). Pharmacologic 
(medications) and nonpharmacologic (cognitive stimulation, physical exercise) therapeutic 
approaches cannot cure the disease or slow the patient’s decline, but may provide a slight 
improvement in symptoms (Alzheimer’s Association, 2017).    
 A groundbreaking cure for Alzheimer’s disease may be decades ahead. Thus, in the 
near future, it will be important to investigate the effect of symptom-modifying treatments. 
This aim was also recommended in a report from the Alzheimer’s Association in 2012, which 
specifically emphasized the importance of investigating symptom-modifying approaches 
(Alzheimers Association, 2012).        
 There are several suggestions regarding why tDCS may have beneficial effects in 
Alzheimer’s disease (Hansen, 2012; Yu, Park & Sim, 2014). First, as previously noted, 
Alzheimer’s disease is associated with impaired neuroplasticity (Koch et al., 2012). Thus, 
impaired neuroplasticity may be a potential target for intervention (Kumar et al., 2017; Rajji, 
2019). Increased neuroplasticity through tDCS may lead to improved memory functions (Hill, 
Kolanowski, & Gill, 2011). Second, in Alzheimer’s disease, there is generally reduced 
excitability within and atrophy of the temporal cortex (Tapia-Arancibia et al., 2008). tDCS 
stimulation aims to improve such reduced excitability. Third, tDCS may increase levels of 




important for learning and memory. Alzheimer’s disease is linked to a reduction in 
acetylcholine, and increasing levels of acetylcholine may be beneficial in Alzheimer’s disease 
(Naik et al., 2009). Cholinesterase inhibitors (e.g., rivastigmine) are widely used in 
Alzheimer’s disease to enhance the levels of acetylcholine (Naik et al., 2009). Fourth, 
Alzheimer’s disease is also associated with low levels of glutamate (Li & Tsien, 2009). tDCS 
may facilitate the glutamatergic process (Hone-Blanchet et al. 2016). Fifth, since Alzheimer’s 
disease leads to a reduction in BDNF (Lee et al., 2005), tDCS may improve neuroplasticity by 
increasing BDNF (Fritsch et al., 2010).        
 If these mechanisms of tDCS can be beneficial for patients with Alzheimer’s disease, 
it may slow the progression of the disease. However, it would be more realistic to expect that 
tDCS may be a symptom-modifying treatment. tDCS in Alzheimer’s disease may serve as a 
symptom-modifying treatment by slowing cognitive decline and/or improving cognitive 
functions for a short period of time.         
 It is of utmost importance to test whether tDCS can be a symptom-modifying 
treatment in Alzheimer’s disease. To date, nine published studies have investigated the 
efficacy of tDCS as a cognitive enhancer in patients with Alzheimer’s disease. There is still 
limited evidence of tDCS as a symptom-modifying treatment in patients with Alzheimer’s 
disease.           
 In the following studies, tDCS in Alzheimer’s disease was investigated. Ferrucci and 
colleagues (Ferrucci et al., 2008) investigated the effect of three 15-minute sessions of tDCS 
stimulation for patients with Alzheimer’s disease; temporoparietal areas were stimulated. 
They found that scores on a word recognition test significantly improved, by 17% for anodal 
stimulation compared to the results for placebo and cathodal tDCS stimulation.   
 Similarly, Boggio and colleagues (Boggio et al., 2009) delivered three 30-minute 




stimulation of the frontal cortex and placebo stimulation in random order. The results revealed 
that stimulation of the temporal cortex led to significantly better scores on a visual recognition 
task.            
 Furthermore, Boggio and colleagues (Boggio et al., 2012) employed tDCS stimulation 
of the temporal cortex. Each session lasted 30 minutes and was delivered for five consecutive 
days. The results revealed that active tDCS stimulation improved visual recognition by nine 
percent compared to a two-and-a-half percent improvement for placebo tDCS. The 
improvement from the active tDCS stimulation persisted for a month after the last stimulation 
session.             
 Another study by Khedr and colleagues (Khedr et al., 2014) reported that ten sessions 
of 25 minutes of tDCS stimulation of the prefrontal cortex led to a significantly increased 
score on Mini Mental Status Examination (MMSE) compared to the scores achieved after 
placebo tDCS. The MMSE score improved by two points immediately after active tDCS 
stimulation. This improvement increased by two more points at the two-month follow-up. In 
comparison, placebo tDCS stimulation improved the MMSE scores by 0.4 points at the two-
month follow-up.          
 Cotelli and colleagues (Cotelli et al., 2014) used frontal cortex stimulation with ten 
tDCS sessions in combination with computerized memory training. They investigated how 
this intervention could improve face-name associations. There was no significant difference 
between placebo and active tDCS stimulation in name-face associations.   
 Additionally, Suemoto and colleagues (Suemoto et al., 2014) applied tDCS over the 
frontal cortex for six sessions during a period of two weeks. The aim of the stimulation was to 
reduce apathy due to Alzheimer’s disease. No significant differences were found between 
active and placebo tDCS.         




groups, a placebo group and an active group. Each patient underwent 10 sessions of tDCS 
stimulation for a total of 40 minutes. The stimulation sites were both the left and right 
temporoparietal cortices for 20 minutes on each side. They found that active tDCS led to 
significant improvements on cognitive test results (the MMSE, clock drawing test, and 
Montreal Cognitive Assessment), whereas no such results were found in the placebo group.    
 Furthermore, Im and colleagues (Im et al., 2019) randomized patients into either active 
or placebo tDCS groups that would undergo daily 30-minute stimulation sessions at home for 
six months. Compared to the placebo group, active tDCS led to significant changes on 
cognitive test results (MMSE, Boston Naming Test). However, no such effect was observed 
for delayed recall. The regional cerebral metabolic rate for glucose (rCMRglc) in the 
temporal/inferior gyrus was preserved in the active group but was reduced in the placebo 
group.             
 The results from some of these Alzheimer’s studies are promising. However, there are 
central methodological limitations, and tDCS cannot be seen as an adjuvant intervention in 
Alzheimer’s disease (Buss, Fried, & Pascual-Leone, 2019; Kim, 2016). First, an important 
limitation is that most tDCS studies focus on immediate effects (James Giordano et al., 2017; 
Hsu et al., 2015). The application of tDCS as a therapeutic for Alzheimer’s disease seems 
unlikely without more evidence of its long-term effects. There is clearly a need to study the 
long-term effects of tDCS in Alzheimer’s disease (Cruz Gonzalez et al., 2018).   
 In their study, Im and colleagues (Im et al., 2019) applied a long-term intervention (for 
six months). However, we do not know whether the effect of the six-month tDCS intervention 
persisted after the last stimulation session. In general, very few studies have investigated the 
long-term effects of tDCS, so the long-term effect is unknown (Cruz Gonzalez et al., 2018; 
Vestito, Rosellini, Mantero, & Bandini, 2014).        




2016). Such small-powered studies limit generalizability. Thus, the results from the above 
studies must be interpreted with caution.      
 Third, previous studies have relied on less advanced cognitive outcome measures. 
Most studies relied on gross cognitive screening tools rather than neuropsychological tests 
with better accuracy for testing specific cognitive functions. Two previous reviews 
recommended that future studies on tDCS and Alzheimer’s disease rely on more sophisticated 
cognitive outcome measures (Freitas, Mondragón-Llorca, & Pascual-Leone, 2011; Nardone et 
al., 2011).                  
 In this thesis, report I sought to overcome some of these methodological shortcomings. 
We applied a randomized, placebo-controlled (RCT) design and applied more comprehensive 
cognitive outcome measures. This application was in accordance with the recommendations 
from previous reviews (Freitas et al., 2011; Nardone et al., 2011). 
Memory functions           
 All reports (report I, report II, and report III) in this thesis involve memory functions. 
In report I and report II, memory functions were the primary outcome measures, whereas in 
report III cognitive and neurobiological aspects of memory were investigated.   
 Memory can be defined as the capacity of the brain to acquire and retain usable skills 
and new information (Baddeley, 1999). For both humans and animals, memory functions are 
core cognitive domains. Human memory can be divided into explicit and implicit memory 
(Schacter, 1992). Explicit memory relies on conscious effort, while implicit memory is more 
automatic/unconscious (Purves et al., 2008). Recalling information during an exam is an 
example of explicit memory, whereas riding a bike is an example of implicit memory.
 Encoding, storing and recall are the core processes of explicit memory function. 
Encoding refers to processing the information so it can be stored, while storage is the 




(Gazzaniga & Heatherton, 2015). Hermann Ebbinghaus was the first psychologist who 
studied our ability to recall information (Gazzaniga & Heatherton, 2015). He created 
nonsense syllables and tried to remember a list of such syllables. He discovered, using himself 
as the only research participant, that the ability to recall the information occurred rapidly 
during the first hours and days, and later, there was a more steady, gradual decline (Pashler, 
Rohrer, Cepeda, & Carpenter, 2007). This theory is often termed “the forgetting curve” or 
“Ebbinghaus curve”. In addition, he also found that overlearning and repetition decreased 
forgetting and could improve recall (Pashler et al., 2007).     
 Memory and learning are closely related concepts. However, there are some 
differences. Learning is the process of acquiring memory, while memory is a behavioral 
change caused by an experience (Gazzaniga & Heatherton, 2015). For instance, the ability to 
acquire new words is learning, whereas the ability to recall the words is memory (Okano, 
Hirano, & Balaban, 2000). tDCS aims to improve both learning and memory.   
 Explicit memory can be divided into episodic and semantic memory (Baddeley, 1999). 
Semantic memory relies on facts, knowledge and concepts, whereas episodic memory builds 
on events and experiences (Tulving, 2001). Contrary to semantic memory, episodic memory 
relies on the recollection of past experiences (Tulving, 1985). For instance, to know that a 
bike has two pedals is semantic memory and memories of riding a bike in the past are 
examples of episodic memory. The ability to recall a list of words is an example of episodic 
memory, more specifically verbal episodic memory.     
 Episodic memory can be divided into three parts: immediate recall, delayed recall and 
recognition (Delis, Kramer, Kaplan, & Ober, 2004). Immediate recall are memories we can 
recall without delay, for instance, repeating a history instantly. Delayed recall is our ability to 
remember knowledge, information or past experiences after either short (ten minutes) or long 




colleagues (Squire, Genzel, Wixted, & Morris, 2015) define consolidation as follows: 
“Consolidation refers to the process by which a temporary, labile memory is transformed into 
a more stable, long-lasting form”. Consolidation is our ability to transfer memory material 
from immediate memory to long-term memory (Carlson, 2013) and also describes a newly 
formed memory going through a transformation process in which the memory becomes 
stronger and more resilient (Alberini, 2005).      
 Weston and colleagues revealed that delayed recall after seven days is a predictor for 
developing Alzheimer’s disease (Weston et al., 2018). Delayed recall is also found to be a 
stronger predictor for Alzheimer’s disease than both structural imaging and cerebrospinal 
fluid biomarkers (Gomar, Bobes-Bascaran, Conejero-Goldberg, Davies, & Goldberg, 2011). 
To distinguish age-related memory decline from Alzheimer’s disease, delayed recall (of a 
word-list) has a sensitivity and specificity of 89% (Weissberger et al., 2017). One study 
(Chandler et al., 2004) found that only three percent of healthy elderly adults had difficulties 
with delayed recall of three words. For patients with Alzheimer’s disease, 87 % recalled no 
words or one word.          
 Unlike recall, recognition involves a cue. Recognition is the ability to recognize 
previous knowledge, for instance, to recognize family members and places. Both depression, 
cerebrovascular disease (vascular dementia) and Lewy body dementia are associated with 
delayed recall, whereas recognition is intact (Shankle et al., 2005).   
 A useful framework for understanding the relation between immediate recall and 
delayed recall is the Atkinson-Shiffrin model of memory (Atkinson & Shiffrin, 1968). In this 
model, short-term memory is responsible for short-term storage and is able to hold 
information for 20-30 seconds. Short-term memory has a rapid rate of forgetting. Immediate 
recall requires short-term memory. The information from short-term memory can be stored 




model, short-term memory is similar to a bottleneck since the information must pass from 
short-term memory to be stored in long-term memory. Long-term memory has a large storing 
capacity, but quite the opposite is true for short-term memory (Higbee, 2001). Short-term 
memory can be compared to an in-basket on an office desk, whereas the long-term memory 
would be like the file cabinet in an office (Higbee, 2001).       
 The Atkinson-Shiffrin model is widely used, despite its simplicity. Studies of brain 
lesions provide evidence for this model (Gazzaniga & Heatherton, 2015; Squire, 2009). 
People with severe hippocampal lesions can have intact short-term memory and are able to 
recall information immediately, even if their consolidation process is severely affected 
(Squire, 2009). The Atkinson-Shiffrin model is criticized for being too simple and does not 
emphasize the importance of working memory (the active processing of information for 
current use) (Baddeley, 1994).         
 There may be a difference between verbal and visual memory when people recall 
information (Lezak, Howieson, Bigler, & Tranel, 2012). Verbal memory is our ability to 
remember verbal information, e.g., an instruction or a postal address. Visual memory refers to 
our ability to remember visual information/knowledge, e.g., a picture or an illustration. Thus, 
there are different neuropsychological tests for the assessment of either visual or verbal 
memory (Lezak et al., 2012). The present thesis focuses on verbal memory.  
 Memory functions can be assessed with standardized neuropsychological batteries 
(Lezak et al., 2012). A typical memory test for assessing verbal memory is a list-learning task 
in which the patients/participants are presented with a list of words. Then, they are instructed 
to recall the list immediately, after a delay and to recognize which words were presented 
(Delis et al., 2004). Assessing the ability to recall words from a list is one of the most 
common ways to investigate memory functions, both experimentally and clinically (Gavett et 




 Memory functions decline with increasing age. However, to state that all memory 
functions decline with aging is an oversimplification. Compared to episodic memory, 
semantic memory and implicit memory are much more resistant to aging (Schaie & Willis, 
2010). In addition, there is large individual variability within the elderly population. For 
instance, it is found that subsamples of people aged 70 years and older outperformed people 
in middle age on memory tests (Habib, Nyberg, & Nilsson, 2007). Furthermore, the study 
design may also affect how age-related memory declines are detected. Cross-sectional designs 
seem to present earlier declines in age-related memory compared to that of longitudinal 
designs (Schaie & Willis, 2010). 
Hippocampus  
The hippocampus is located in the temporal lobe and is a key brain structure for consolidation 
(Ramirez et al., 2013). Patient H. M had both of his hippocampi removed after epilepsy 
surgery. Due to the surgical procedure, H. M lost his ability to consolidate new information 
(Scoville & Milner, 2000). His delayed recall was severely impaired. He could remember past 
events prior to the surgery but was unable to remember any new information after the surgery. 
His condition led neuroscientists to understand the importance of the hippocampus for the 
formation of new episodic and semantic memories.      
 The hippocampus tends to atrophy with aging. From the age of 60 years, the volume 
of the hippocampus has an annual reduction of one–two percent (Raz et al., 2005). A form of 
hippocampus atrophy is a part of normal cognitive aging and may be responsible for the 
reduction in episodic memory that most people experience in old age (Bartsch & Wulff, 
2015). It is assumed that age-related memory decline is caused by a reduced ability to 
consolidate new information (Kukolja, Goreci, Onur, Riedl, & Fink, 2016).In Alzheimer’s 
disease, the hippocampus is seriously affected, even in the early stage (Querfurth & LaFerla, 




hippocampus and then spreads throughout the brain (Khan et al., 2014). Early deterioration of 
the entorhinal cortex and hippocampus (Criscuolo et al., 2017) could explain why delayed 
recall is such a sensitive measure of Alzheimer’s disease (Gomar et al., 2011).  
 Memory functions seem to correlate with the relative volume of the hippocampus. The 
volume of the hippocampus (when adjusted for intracranial volume and age) is associated 
with the ability to acquire and remember new words (list-learning) (Pohlack et al., 2014; 
Ystad et al., 2009). In general, verbal memory is more dependent on the left hippocampus 
than on the right hippocampus (Ezzati et al., 2016; Ystad et al., 2009). Furthermore, long-term 
stress and depression can lead to memory impairment as a consequence of hippocampal 
atrophy (Kim, Pellman, & Kim, 2015). Both long-term stress and depression are associated 
with the accumulation of cortisol. Such accumulation may be neurotoxic and can lead to 
atrophy of the hippocampus (Kim et al., 2015; Sapolsky, 1996). It has also been revealed that 
experimentally increased cortisol levels are associated with reduced delayed recall 
(Newcomer et al., 1999).          
 The hippocampus is composed of different segments or “subfields”. The hippocampus 
can be divided into 13 different subfields (Iglesias et al., 2015). The differentiation of such 
subfields requires brain imaging with very high resolution (Iglesias et al., 2015). Among these 
subfields are four well-known subfields, called “cornu ammonis” (Andersen, Morris, Amaral, 
O'Keefe, & Bliss, 2007). These subfields range from CA1 to CA4 and seem to have 
specialized functions. In case-control studies using the California Verbal Learning Test II 
(CVLT-II), it was found that the volume of the CA1 correlated better with delayed recall, 
whereas CA2-3 and CA4 were more related to immediate recall (Mueller, Chao, Berman, & 
Weiner, 2011; Mueller et al., 2012). These studies also found that focal lesions in CA1 can 
aggravate autobiographical memory and mental time travel (Thorsten Bartsch, Döhring, Rohr, 




related to hippocampus volume and these subfields.      
 The medial temporal lobe consists of the hippocampus, entorhinal cortex, perirhinal 
cortex and parahippocampus (Carlson, 2013). It is difficult to separate these areas in detail 
with regard to distinct functions (Lipton & Eichenbaum, 2008). However, it seems that the 
hippocampus and parahippocampus contribute to consolidation, while the entorhinal and 
perirhinal cortex contributes more to recognition (Eichenbaum, Yonelinas, & Ranganath, 
2007). One fMRI study found that the parahippocampus was significantly more activated 
when people viewed spatial information (e.g., rooms, landscapes) compared to faces or 
objects (Epstein & Kanwisher, 1998).        
 The medial temporal lobe is vital for declarative memory (Purves et al., 2008; Squire 
& Zola-Morgan, 1991). Medial temporal lobe injuries can lead to difficulties with memory 
function (Squire & Zola-Morgan, 1991). For the detection of dementia, medial temporal 
atrophy can be a sensitive measure (Burton et al., 2008). The sensitivity for distinguishing 
patients with Alzheimer’s disease and healthy controls is 83-84% (Wei et al., 2019; Westman 
et al., 2011).            
 Bikson and colleagues found that tDCS stimulation could stimulate the hippocampus 
in rats (Bikson et al., 2004). One mechanism governing this response is that tDCS increases 
brain-derived neurotrophic factor (BDNF) in rats, which may affect the hippocampus (Yu, 
Wu, Chien, & Hsu, 2019). In humans, we do not know whether tDCS can affect the 
hippocampus. However, it is possible to stimulate the temporal lobe where the hippocampus 
is located. Therefore, the aim for reports I and II in this thesis was to stimulate the temporal 
lobe.     
General research questions 
The major research questions in this thesis were how tDCS can improve verbal memory 




associated with hippocampus volume. Studies in this thesis aimed to supplement the existing 
literature. 
The research questions in this thesis are as follows: 
1) Can active anodal tDCS lead to significantly better verbal memory function compared 
to that observed after placebo tDCS in patients with Alzheimer’s disease? 
2) Can active anodal tDCS lead to significantly better verbal memory function compared 
to that after placebo tDCS in healthy elderly and heathy younger participants? 
3) Are higher scores on CVLT-II associated with a larger volume of the subfields (CA1-
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Participants            
 In report I, a total of 26 patients with Alzheimer’s disease were enrolled in the study. 




«NINCDS-ARDRA» criteria for Alzheimer’s disease (McKhann et al., 2011). We followed 
section 4.2 in these criteria: “probable Alzheimer’s disease with increased level of certainty.” 
This determination of eligibility requires documentation of a progressive cognitive decline 
based on information from informants (relatives) and a cognitive and/or neuropsychological 
evaluation. There were 13 patients in the placebo group and 12 patients in the active group. 
Patients were not eligible if they had serious somatic disorders (cancer, chronic obstructive 
pulmonary disease, heart failure) or neuropsychiatric disorders (psychosis or severe 
depression) that could influence cognitive function.      
 In report II, a total of 40 participants were included in the study. There were two 
groups of participants: one group of young participants (age 20-30 years) and another group 
of participants in later adulthood (age 60-69 years). Participants were required to be healthy, 
i.e., could not suffer from any serious diseases (cancer, heart failure, stroke) or 
diseases/injuries in the central nervous system. In addition, participants were not eligible if 
they had any mental disorders (e.g., depression, anxiety, etc.). No participants decided to 
withdraw from the study.          
 In report III, a total of 47 right-handed participants (31 females, age 20-71 years) were 
included in the study and tested with the California Verbal Learning Test II (CVLT II) and 
two subtests of the Wechsler Abbreviated Scale of Intelligence (WASI). All participants were 
required to be healthy. They could not suffer from any serious somatic diseases or mental 
disorders. Since the study involved brain imaging with magnetic resonance imaging (MRI), 
pregnancy or body implants were exclusion criteria. 
Recruitment methods/randomization        
 In report I, patients with Alzheimer’s disease were recruited by advertisement in the 
local newspaper. In addition, a secretary at the Geriatric Department, University Hospital of 




disease. In reports II and III, participants were recruited by both advertisements in the 
newspaper and at the university and by sending out an invitation letter to the Tromsø senior 
university (an organization where retired individuals meet and discuss science/politics). 
 In reports I and II, patients/participants were randomized to either active or placebo 
tDCS. Patients/participants were assigned to a list with codes provided by the tDCS 
manufacturer. Each patient/participant received his/her own unique code. The code decided 
whether the tDCS stimulator should deliver placebo or active stimulation. We used 
random.org (www.random.org) to randomize the order of the codes. It was not possible to 
identify the codes during the study. After the experiments in reports I and II were completed, 
the list was decoded. Neither the participant/patient nor the experimenter could identify if the 
stimulation was active or placebo, since they only had the code. 
Memory assessment with the California Verbal Learning Test II (CVLT-II)  
 In all three reports (reports I, II and III), we used the California Verbal Learning Test-
II (CVLT-II) to assess verbal memory functions. CVLT-II is a widely used memory test, 
normed by age and sex (Delis et al., 2004). CVLT-II assesses immediate recall, delayed recall 
and recognition (Delis et al., 2004). More specifically, CVLT-II measures verbal auditory 
episodic memory. Additionally, CVLT-II measures serial position effects (primacy and 
recency), cued recall, intrusions and interference (Delis et al., 2004).    
 In reports I and II, CVLT-II was our primary outcome measure, while the study 
conducted for report III investigated how CVLT-II correlated with hippocampal subfields. 
When using CVLT-II, the participant/patient was presented with a 16-word list. This 
presentation was performed five times. The patient/participant was instructed to recall the list 
immediately after each presentation. Recalling this list immediately assesses immediate 
memory. After a delay of 20 minutes, the patient/participant was asked to recall all the words 




word-list containing 32 words and was instructed to say “yes”/“no” if the word was 
recognized (i.e., was presented on the 16 words list). Such “yes”/“no” responses requires 
recognition.            
 CVLT-II can be used  both experimentally for healthy participants and to assess 
memory functions before and after a treatment, surgical procedure or disease (Delis et al., 
2004). In general, test-retest practice effects can be prominent for memory tests (Benedict, 
2005). However, using parallel versions of memory tests minimizes the test-retest practice 
effect (Benedict & Zgaljardic, 1998). Thus, CVLT-II consists of two parallel versions: 
“standard” and “alternate” versions. These two versions have different and independent word 
lists to reduce test-retest practice effects.      
 CVLT-II is widely used in both research and clinical practice to assess patients with 
Alzheimer’s disease (Delis et al., 2005). A patient with Alzheimer’s disease will typically find 
the CVLT-II delayed recall task very difficult (Rabin et al., 2009). The delayed recall task 
requires consolidation of verbal information, and in Alzheimer’s disease, such consolidation 
is impaired (Mayeux, 2010). Younger participants scored significantly better than healthy 
elderly on immediate and delayed recall tasks, whereas patients with Alzheimer’s disease 
scores significantly lower than healthy elderly on immediate recall, delayed recall and 
recognition tasks (Delis et al., 2004).        
 In a Norwegian study by Bosnes (Bosnes, 2007), a significant correlation was found 
between CVLT-II and Wechsler Memory Scale Revised (WMS-R) scores for delayed recall (r 
= 0,58, p < 0,001). Other studies have assessed patients using the CVLT-II, e.g., patients with 
depression (Hammar, Isaksen, Schmid, Årdal, & Strand, 2011), chronic pain (Landrø et al., 
2013), bipolar disorders and schizophrenia (Simonsen et al., 2009). There are no Norwegian 
norm data for the CVLT-II (Siqveland, Sundseth, Dalsbø, Harboe, & Leiknes, 2014), and all 




 The age norms for the CVLT-II data are based on cohorts (i.e., cohorts were aged 60-
69 years, 70-79 years, etc.) (Delis et al., 2004). The CVLT-II has good test-retest reliability. 
For immediate recall, the test-test reliability is 0,82, whereas for delayed recall, the test-
retestreliability is 0,88 (Delis et al., 2004). For recognition, the test-retest reliability is 0,79 
(Delis et al., 2004).          
 There is a short format of the CVLT-II, consisting of nine words. This short format is 
very suitable for patients with Alzheimer’s disease and other forms of dementia (Delis et al., 
2004). However, this format does not have any parallel versions and may increase the 
probability of test-retest practice effects. 
Transcranial direct current stimulation (tDCS) 
In reports I and II, we used a transcranial direct current stimulation (tDCS) device from 
NeuroConn, Ilmenau, Germany. In both studies (reports I and II), the stimulation duration for 
each session was 30 minutes, and the current intensity was 2 mA. This outcome was in line 
with previous recommendations (Brunoni et al., 2012; Monte-Silva et al., 2013; Thair et al., 
2017). We used a pair of 35-cm2 rubber electrodes covered with sponges to deliver the 
current. These electrodes were placed at the skull. The stimulation electrode (“the anode”) 
was placed over the temporal cortex at the T3 position, according to the 10-20 system (a 
system used for electroencephalographic electrode positioning).  This positioning was similar 
to that used by Boggio and colleagues (Boggio et al., 2012), and targeting the temporal lobe is 
recommended for memory improvement in Alzheimer’s disease (Zhao et al., 2017). We 
aimed to enhance verbal memory function. The left temporal cortex plays a major role in 
verbal memory (Frisk & Milner, 1990; Johnson, Saykin, Flashman, McAllister, & Sparling, 
2001), so we wanted to target this area. The reference electrode (“the cathode”) was placed on 




duration and electrode positioning were identical in both the placebo and active tDCS groups. 
Figure 1 and Figure 2 show the procedure of tDCS stimulation in reports I and II. 
 
Figure 1: The tDCS procedure in report I. 
 
 








tDCS and adverse effects 
The small number of reported adverse effects may contribute to the increased interest in tDCS 
(Brunoni et al., 2011). In the literature, it is emphasized that tDCS is associated with very few 
and minor adverse effects. This outcome was also the conclusion from a systematic review 
conducted by Brunoni and colleagues (Brunoni et al., 2011). They identified the adverse 
effects of tDCS in 117 studies with human participants. Adverse effects were usually minor. 
In most cases, the adverse effects were itching, tingling, headache, a burning sensation and 
discomfort. However, one study reported that tDCS stimulation led to mania (Kalu, Sexton, 
Loo, & Ebmeier, 2012).            
 Despite the fact that tDCS is associated with very minor adverse effects, it is difficult 
to know exactly where the safety limit is in regard to current strength and duration. However, 
a previous safety review concluded that a duration below 40 minutes and a current strength of 
less than 4 mA did not produce any serious adverse effects or injuries (Bikson et al., 2016). 
These recommendations were based on a review of 33200 sessions and 1000 participants with 
repeated sessions.            
 A registration questionnaire is available that queries participants about adverse effects. 
This questionnaire was developed by Brunoni and was translated to Norwegian by Fagerlund 
(Fagerlund et al., 2015). When using this questionnaire, the experimenter is instructed to ask 
for adverse effects (adverse effects, i.e., itching, headache, nausea, and redness). In report II, 
we included this questionnaire. We found it especially important to be aware of possible 
adverse effects since we used a novel tDCS stimulation protocol (with short intervals between 
each session, also referred to as “accelerated tDCS”). In report I, we decided to reject the 




disease to report adverse effects based on a questionnaire since the questionnaire requires 
retrospective memory. Thus, we asked all patients and their caregivers (who accompanied 
them to the lab) to observe and report possible adverse effects.      
 In both report I and report II, no adverse effects were reported or observed. We cannot 
generalize these findings to other studies. However, we can assume that tDCS is associated 
with few adverse effects in healthy participants and patients with Alzheimer’s disease. The 
tDCS protocols applied in report I and report II (six 30-minute sessions over a two-week 
period and three 30-minute sessions for two consecutive days, respectively) seem to be very 
well tolerated.    
Ethical considerations                           
The procedures and methods in report I, report II and report III were approved by the 
Regional Committee for Research Ethics in Medicine and Health Sciences (2012/1890) and 
were conducted in accordance with the Declaration of Helsinki.    
 In report I, patients with Alzheimer’s disease had to sign an informed consent form. 
To provide this consent, they had to understand the consequences of their participation. All 
patients and their caregivers received verbal and written information about the study. Prior to 
participation, we had a meeting with each patient and his/her caregiver during which we 
discussed different aspects of the informed consent and consequences of participation. During 
the meeting, we ensured that the patients understood the information. The potential benefit of 
participation (improved memory function) outweighed the risks (minor adverse effects). 
Additionally, we ensured that the patients relative (e.g., wife or son) understood the purpose 






Summary of reports I-III 
 
Report I: Bystad, M., Grønli, O., Rasmussen, I.D. Gundersen, N., Nordvang, L., Wang-
Iversen, H. & Aslaksen P.M. (2016). Transcranial direct current stimulation as a memory 
enhancer in patients with Alzheimer`s disease: A randomized placebo controlled 
trial. Alzheimer`s Research & Therapy, 8, 1-7. 
The aim of this randomized placebo-controlled trial was to investigate tDCS as a memory 
enhancer in patients with Alzheimer’s disease. We aimed to improve verbal memory 
functions since impaired verbal memory is a core symptom of Alzheimer’s disease (Mayeux, 
2010). Hence, the stimulation electrode (anodal) was placed above the left temporal lobe. As a 
background for further research, we relied on the results of Boggio and colleagues (Boggio et 
al., 2012), who found that tDCS stimulation of the temporal lobe improved recognition 
memory for a month after the last stimulation session.      
 We used a double-blinded, randomized placebo-controlled trial (RCT) to compare the 
effects of active tDCS with that of placebo tDCS. Patients with Alzheimer’s disease were 
randomized into two groups: an active group and a placebo group. Both groups underwent the 
same procedure, except that the placebo group did not receive active current during the 
stimulation. Patients in the active group received 2 mA stimulation, lasting for 30 minutes. 
Six stimulation sessions were delivered over a period of two weeks.    
 The primary outcome measure was verbal memory, assessed with the California 
Verbal Learning Test II (CVLT-II). This is a neuropsychological test, normed by age and sex. 
To reduce test-retest practice effects, we used two parallel versions of the CVLT-II (standard 
and alternative versions). These versions have different lists of words to remember. 
Secondary outcome measures included the Mini Mental Status Examination (MMSE), the 
clock-drawing test and Trail Making Test A and B.      




active and placebo tDCS. A nonparametric Mann-Whitney U test was used due to the 
violation of normally distributed data. This analysis failed to reveal any significant differences 
between active and placebo tDCS on both primary and secondary outcomes.  
 For the primary outcome measure (verbal memory function), we did not find any 
significant differences between active tDCS and placebo tDCS for either CVLT-II immediate 
recall, delayed recall or recognition. For secondary outcome measures (Trail Making Test A, 
the Mini Mental Status Examination and the clock-drawing test), no significant differences 
between active and placebo tDCS results were found. None of the patients had any adverse 
effects. 
Report II: Bystad, M., Storø, B., Gundersen, N., Wiik, I.L., Nordvang, L., Grønli, O., Daae-
Rasmussen, Aslaksen, P.M. Can accelerated transcranial Direct Current Stimulation improve 
memory functions? An experimental, placebo-controlled study. Submitted to Heliyon).  
The aim of this experimental study was to assess the effect of tDCS on memory functions in 
healthy participants. We relied on previous recommendations (Nitsche et al., 2015) where 
short intervals between each tDCS session could improve the effects. We wanted to 
investigate how tDCS with short intervals could affect memory functions. Such short intervals 
involve giving tDCS for 30 minutes and then repeating the tDCS session within a 30-minute 
timeframe. This type of protocol is novel and is referred to as “accelerated tDCS”. 
 We used a double-blind placebo-controlled design. Half of the participants received 
active tDCS, while the rest received placebo tDCS. This study was randomized. Neither the 
participant nor the research assistant knew if the tDCS device delivered placebo or active 
stimulation.            
 Each participant received a total of six tDCS sessions. These six sessions were 
conducted for two consecutive days. Three 30-minute sessions of tDCS were conducted each 




mA. The stimulation electrode (anodal) was placed above the left temporal lobe.  
 The primary outcome measure was verbal memory. This measure was assessed with 
the California Verbal Learning Test II (CVLT-II) before the first session and after the sixth 
session. We used two parallel versions of the CVLT-II (standard and alternative) to limit the 
test-retest practice effects. Secondary outcome measures were digit span from the Wechsler 
Memory Scale (WMS) and Trail Making Test A and B. We also used the vocabulary and 
matrix reasoning aspects from Wechsler’s Abbreviated Scale of Intelligence (WASI) initially 
to control for general intellectual abilities.        
 We conducted independent t-tests to investigate the differences in the mean score 
change between placebo and active tDCS groups. MANOVA was conducted to investigate 
group differences between placebo and active tDCS groups adjusted for age. We did not find 
a significant difference between placebo and active tDCS groups for verbal memory 
functions, neither for the young nor for the elderly participants. For all the participants (N = 
40), our analysis showed no significant differences in CVLT-II score changes for the active 
and the placebo tDCS groups (baseline – post 2). No significant differences were found 
between the active and placebo tDCS groups for CVLT-II immediate recall, CVLT-II delayed 
recall, or CVLT-II recognition scores. For TMT B, active tDCS led to significantly better 
scores than placebo tDCS. For WMS digit span scores, there was no significant difference 
between the active and placebo groups.        
 For the group of elderly participants (N = 20), we found no differences in the CVLT-II 
scores between the active and placebo tDCS groups. We found no significant differences 
between active and placebo tDCS groups for CVLT-II immediate recall, CVLT-II delayed 
recall and CVLT-II recognition scores. There was no significant difference between the active 
and placebo groups for TMT A and TMT B and digit span scores. In the group of younger 




tDCS groups. No significant differences were found between the active and placebo tDCS for 
CVLT-II immediate recall, CVLT-II delayed recall and CVLT-II recognition. There were no 
significant differences between the active and placebo groups for TMT-A and digit span 
scores. For the young participants, the active tDCS group performed significantly better than 
the placebo tDCS group on TMT-B.         
 
Report III: Aslaksen, P.M., Bystad, M.K., Ørbo, M.C. & Vangberg, T.R. The relation of 
hippocampal subfield volumes to verbal episodic memory measured by California Verbal 
Learning Test II in healthy adults. Behavioral Brain Research, 351, 131-137. 
The aim of the study was to investigate the association between separate hippocampal 
subfields and verbal memory performance in healthy participants. The hippocampus can be 
divided into 13 segments. In our study, we aimed to investigate four subfields: CA1-CA4. 
These four subfields may have specialized functions, and the volume of the hippocampal 
subfields seems to be positively correlated with memory function. However, few studies have 
investigated the relationship between hippocampal subfields and cognitive functions. Verbal 
memory seems to be associated with the left hippocampus rather than the right hippocampus 
(Ezzati et al., 2016).           
 A total of 47 healthy adults participated in the study. Of these participants, there were 
31 females, and the age range was 20-71 years. The mean education level was 13,78 years 
(SD = 2,02). All participants were right handed.       
 To assess general cognitive functions, we applied two subtests of Wechsler’s 
Abbreviated Scale of Intelligence (WASI) (Pearson, 1999). These two subtests were matrix 
reasoning and vocabulary. Matrix reasoning is a nonverbal subtest that assesses visuospatial 
problem solving, while the vocabulary subtest requires the participant to explain words with 




scores using age norms. To assess verbal memory, we applied a Norwegian version of the 
California Verbal Learning Test II (CVLT-II).      
 Participants were scanned with a 1,5 T Phillips Intera MR scanner using an 8-channel 
head coil. Within a month after the cognitive testing, MRI scanning was performed for all 
participants. Hippocampal subfield segments were analyzed using FreeSurfer 6.0. 
(https://surfer.nmr.mgh.harvard.edu/).        
 The data were normally distributed. Thus, independent samples t-tests were used to 
investigate group differences in unadjusted volumes, whereas paired samples t-tests were 
applied to investigate differences between the right and left formations. Correlations between 
CVLT-II subtests and hippocampal volumes were evaluated with Pearson correlations. To 
reduce the probability of type I errors and to adjust p-values for multiple testing, p-values 
were adjusted with the false discovery rate (FDR) procedure. There were no significant 
correlations between the CVLT-II delayed recall scores and the right hippocampal subfields. 
However, significant correlations were found between CVLT-II immediate recall scores and 
volumes of the left CA 1-4 subfields. For the left CA1 subfield, the correlation for immediate 
recall was r = 0,30, while the correlation for delayed recall was r = 0,43. For the left CA2-3 
subfields, the correlation for immediate recall was r = 0,43, while the correlation for delayed 
recall was r = 0,41. For the left CA4 subfield, the correlation for immediate recall was r = 
0,42, while the correlation for delayed recall was r = 0,47.      
 Our results support the assumption that verbal memory is related to the left 
hippocampus volume. It also suggests that the left hippocampus volume reflects the CVLT-II 
score. This relation strengthens the utility of the CVLT-II as a measure of verbal memory. 








The aim of the experimental tDCS studies (reports I and II) was to investigate the efficacy of 
tDCS as a memory enhancer in both healthy participants and patients with Alzheimer’s 
disease. In addition, we wanted to investigate the relationship between verbal memory 
performance and volume of the subfields of the hippocampus.     
 In both reports I and II, we expected to find that active tDCS led to significantly 
improved memory compared to that assessed after placebo tDCS. In report III, we expected to 
reveal a significant correlation between hippocampal subfield volumes and verbal memory 
performance.            
 Both report I and report II failed to reveal a significant difference between active and 
placebo tDCS groups for memory improvement. In both studies, we used the CVLT-II to 
assess verbal memory functions. As report III shows, when corrected for age and sex, there 
was a significant positive correlation between CVLT-II scores and the volume of the left 
subfields (CA1-CA4) of the hippocampus. This correlation is in line with previous studies 
(Pohlack et al., 2014) and confirms our hypothesis.      
 The results from report I and report II did not agree with our hypothesis. Thus, our 
results are not in line with results from some of the previous Alzheimer’s disease studies 
(Boggio et al., 2012; Boggio et al., 2009; Ferrucci et al., 2008; Khedr et al., 2014) or healthy 
participants (Manenti et al., 2013; Ross et al., 2011). However, it should be noted that tDCS 
seems to have mixed results in both Alzheimer’s disease (Kim, 2016) and healthy participants 
(Horvath et al., 2015; Tremblay et al., 2014). This outcome makes it difficult to draw precise 
conclusions about the efficacy of tDCS.        
 The lack of significant differences between placebo and active tDCS groups for 




different causes. The tDCS protocols in our studies may not be as efficient as we expected. In 
report I, we delivered six tDCS sessions over two weeks. It is possible that having only six 
stimulation sessions over a period of two weeks may be insufficient for increasing 
excitability. In addition, Alzheimer’s disease is often associated with cerebrovascular lesions 
in the cortex (Attems & Jellinger, 2014). Such lesions may affect the distribution of the 
current to the tissue and current direction, reducing neuroplasticity and regional blood flow 
(Datta, Baker, Bikson, & Fridriksson, 2011; Hong et al., 2017; Pavlova, Semenov, & Guekht, 
2019). Furthermore, in Alzheimer’s disease, a reduction in neuroplasticity may be especially 
pronounced in the temporal cortex (Tapia-Arancibia et al., 2008) and impair the effect of 
tDCS. It is reasonable to assume that these factors can inhibit the effect of tDCS stimulation.
 Since CVLT-II scores seem to reflect left hippocampus size (as revealed in report III), 
it could be assumed that the CVLT-II scores in report I and report II would have improved if 
tDCS stimulation had affected the hippocampus. Thus, our nonsignificant results in report I 
and report II could indicate that the current failed to reach the hippocampus. Without any 
neurophysiological measures, such an explanation should be interpreted with caution.   
 A dose-response relationship is suggested between the number of tDCS sessions and 
efficacy (Brunoni et al., 2012). Two case studies have found that a high number of tDCS 
sessions led to improved memory functions in Alzheimer’s disease (Bystad, Rasmussen, 
Abeler, & Aslaksen, 2016; Bystad, Rasmussen, Grønli, & Aslaksen, 2017). However, the 
optimal tDCS protocol for Alzheimer’s disease has not yet been determined.   
 In report II, we applied a stimulation protocol with short intervals between each tDCS 
session (“Accelerated tDCS”). To our knowledge, our study is the first to investigate 
accelerated tDCS as a memory enhancer. The lack of a significant difference between active 
and placebo tDCS groups could be due to our novel tDCS protocol. Such short intervals 




(Dedoncker, Brunoni, Baeken, & Vanderhasselt, 2016) of 188 tDCS trials investigated how 
the interval between sessions could influence the effects of tDCS on cognitive outcome 
measures. Intervals between sessions ranged from less than 1 hour to up to 2 weeks. It was 
found that the interval between sessions had no influence on cognitive outcome measures, 
neither in healthy participants nor neuropsychiatric patients. The optimal time period between 
sessions and number of sessions remain to be determined in future studies (Cappon, 
Jahanshahi, & Bisiacchi, 2016).        
 However, in report II, we found a significant difference between active and placebo 
tDCS groups for executive functions in the younger participants. A test-retest practice effect 
is a possible explanation since TMT B is prone to test-retest practice effects. For instance, one 
study found that TMT B scores improved by nearly 10 seconds after two weeks (first retest 
session) and by 20 seconds after three months (fourth session) (Bartels, Wegrzyn, Wiedl, 
Ackermann, & Ehrenreich, 2010).       
 Another possible explanation is that cortical areas other than the temporal cortex may 
have been affected (e.g., frontal cortex) in our study, since tDCS may lead to widespread 
alterations of functional connectivity (Keeser, Meindl, et al., 2011). It has been suggested that 
tDCS may enhance alerting attention (Coffman, Trumbo, & Clark, 2012). For instance, it has 
been demonstrated that tDCS stimulates vigilance for up to six hours (McIntire, McKinley, 
Goodyear, & Nelson, 2014), which could lead to better TMT B scores.   
    
General limitations with tDCS                   
 A limitation with tDCS is that there is large individual variability in tDCS responses. 
To illustrate the large variability, Tremblay and colleagues (Tremblay, Beaulé, Lepage, & 
Théoret, 2013) can serve as an example. They reported that one participant experienced a 




can be difficult to identify potential reasons for such variability. However, it is reasonable to 
assume that individual factors can account for at least some of this variability. Differences in 
anatomy (e.g., skull size/thickness) and neurophysiology are important individual differences 
(Woods et al., 2016). Such differences may affect the distribution of current flow to the 
cortex. Hence, a “one size fits all” approach is probably not useful for tDCS.  
 A further limitation is that electrode placement is still an area of uncertainty (Zhao et 
al., 2017). We aimed to stimulate the temporal cortex. We decided to stimulate this area due 
to promising results found in the study by Boggio and colleagues (Boggio et al., 2012). For 
memory enhancement, it was found that the left temporal cortex was a better target for tDCS 
stimulation than the frontal cortex (Zhao et al., 2017). However, for conventional tDCS, the 
precision (spatial resolution) is considered to be low because the target of the stimulation 
usually relies on a cortical area (Datta et al., 2009). Conventional tDCS is associated with 
diffuse electrical fields, which are affected by individual brain anatomy and head shape 
(Mikkonen, Laakso, Tanaka, & Hirata, 2020).      
 Another limitation with tDCS is that interference may affect the tDCS results. It has 
been suggested that cognitive or motor activity during tDCS stimulation can enhance or 
inhibit the effect of tDCS (Horvath, Carter, & Forte, 2014). For instance, in their meta-
analysis, Hsu and colleagues (Hsu et al., 2015) suggested that tDCS treatment in elderly 
individuals and patients with Alzheimer’s disease may be more effective if a cognitive task is 
given during tDCS stimulation. However, one study revealed that imaginary tDCS stimulation 
reduced the effect of anodal tDCS stimulation, whereas it increased the effect of cathodal 
stimulation. The imaginary task was to visualize a motor movement (Antal, Terney, Poreisz, 
& Paulus, 2007). Further, another study applied the motor evoked potential (MEP) measure. 
This application indicates that motor evoked potentials are recorded from muscles due to 




about language, mathematics and history) during tDCS stimulation could interfere with the 
effects (Miyaguchi et al., 2013). They found that such cognitive input reduced the effect of 
both anodal and cathodal tDCS stimulation. Thus, interference may be a limitation with tDCS 
that is difficult to control in experimental studies.        
 Walsh previously summarized the major limitations with tDCS; he emphasized that a 
lack of standardization regarding electrode placement, uncertainty about ecological validity 
(how results from tDCS studies may manifest outside the research lab) and mixed results are 
some of the major shortcomings of tDCS (Walsh, 2013). 
Limitations with our studies         
 All our studies (reports I, II and III) have some central methodological limitations that 
need to be addressed. For report I, a central limitation is our small sample size. There is 
clearly a need to conduct larger clinical trials to assess the effect of tDCS in Alzheimer’s 
disease. A small sample size is also a limitation of report II and report III. A large number of 
tDCS studies rely on small sample sizes. For instance, in a meta-analysis by Hsu and 
colleagues, only two out of 12 studies had a sample size slightly above 30 participants (Hsu et 
al., 2015). A small sample size may increase the risk for a “type II error”. This error can occur 
when a false null hypothesis is retained, i.e., a “false negative”. There may also be a risk for a 
“type I error”, where the false null hypothesis is rejected, i.e., a “false positive”.   
 Recruitment difficulties were the main reason for our small sample sizes in report I 
and report II. Recruiting healthy participants was difficult due to skepticism about the current 
stimulation, i.e., the word “current” can have negative associations. Some participants even 
confused tDCS with electroconvulsive therapy (ECT). We lack data about this confusion. 
However, such considerations should be noted. Failure to recruit the planned number of 
patients within the expected timeframe is a common problem in Alzheimer’s trials (Grill & 




accompany patients to the research lab are typical barriers for studies involving patients with 
Alzheimer’s disease (Grill & Karlawish, 2010).      
 Another limitation is that it can be very difficult to compare our results with results 
from previous tDCS studies since we relied on more advanced memory assessments. While 
the use of a more sophisticated memory assessment is a strength, it also makes comparisons 
with previous studies more difficult. For report I and report II, we do not know if our results 
would have been different if we had relied on the same type of tests that previous studies 
relied on (for instance, the “visual recognition task” or that used by Boggio and colleagues 
(Boggio et al., 2012)).          
 A further methodological limitation with reports I and II is that we relied solely on 
neuropsychological/cognitive outcomes. We did not includeneurobiological 
/neurophysiological outcome measures (e.g., neuroimaging). Consequently, it is uncertain 
whether our stimulation protocol in reports I and II caused any neurophysiological changes. 
 Another limitation is that we lack information about the educational level of the 
participants in report I and report II, so we could not control for this variable. Educational 
level seems to influence episodic memory in both healthy individuals (Angel, Fay, 
Bouazzaoui, Baudouin, & Isingrini, 2010; Ronnlund, Nyberg, Backman, & Nilsson, 2005) 
and among patients with Alzheimer’s disease (Scarmeas, Albert, Manly, & Stern, 2006). 
 In report III, we relied on a relatively small sample size, and the participant’s age span 
was large. These shortcomings limit the generalizability of the results. In addition, we used an 
MRI scanner with a 1,5 Tesla magnetic-field strength. Compared to the 1,5 Tesla magnetic 
field strength, the 3 Tesla magnetic field strength has a higher resolution and is more sensitive 
for the detection of subfields (Winterburn et al., 2013). 
Limitations with memory assessment                           




limitations with this memory assessment that should be taken into account. We used the 
Norwegian version of CVLT-II. However, this Norwegian version is based on American 
norms. While there are similarities with Norwegian and American culture, we do not know 
how representative these norms are in terms of education and health.   
 Another limitation with the CVLT-II and memory assessment in general is ecological 
validity (Dubreuil, Adam, Bier, & Gagnon, 2007). It is difficult to know exactly how scores 
from the CVTL-II in an experimental setting may manifest in real life situations. In other 
words, it is unknown to what degree CVLT-II scores can be related to everyday memory, for 
instance, remembering errands, appointments, new names or details from conversations. The 
ecological validity may be further investigated (Dubreuil et al., 2007). Furthermore, there may 
be a gap between self-reported memory and delayed recall performance (Sohel, Tuokko, 
Griffith, & Raina, 2016). One explanation for this gap could be that memory assessment 
partly fails to detect everyday memory and implicit memory (Dubreuil et al., 2007).  
 A third limitation is that memory assessment can be demanding. Learning a long list 
of words can be overwhelming for patients with memory impairments (e.g., those with 
Alzheimer’s disease). Standard forms of the CVLT-II consist of 16 words, which may be 
excessive. For patients with memory impairments, a short form of CVLT-II exists with only 
nine words (Delis et al., 2004). However, this short form of CVLT-II does not have a parallel 
version and may be prone to test-retest practice effects. 
Strengths with our studies         
 Our studies have several methodological strengths that should be emphasized. A 
strength for report I and report II is that we applied a double-blind placebo-controlled design. 
Therefore, both the experimenter and the participant were unaware of which condition the 
patient/participant was allocated to (placebo or active tDCS).    




testing (CVLT-II) to assess verbal memory functions. As previously noted in this thesis, 
CVLT-II is normed for both sex and age, and it is a widely used neuropsychological tool 
(Delis et al., 2005; Delis et al., 2004). The advantage of relying on a standardized memory test 
is that the results are more likely to have high internal validity and test-retest reliability 
compared to a nonstandardized test.         
 Thus, we relied on a more sophisticated memory assessment than that used in previous 
studies. Two previous reviews suggested that further tDCS studies in Alzheimer’s disease 
should rely on more sophisticated cognitive outcome measures (Freitas et al., 2011; Nardone 
et al., 2011). The application of CVLT-II was in line with that recommendation. 
Neuropsychological testing is the most reliable method for assessing cognitive functions in 
both Alzheimer’s disease and healthy individuals (Lezak et al., 2012).    
 For report III, a strength is that we combined verbal memory assessment (CVLT-II) 
with brain imaging (MRI). MRI is an advanced method that provides the opportunity to 
explore neural aspects of verbal memory functions. In report III, we both have cognitive 
(memory assessment) and neurobiological correlates. 
Implications                       
Our studies may have implications for further research and clinical applications. For report I, 
we demonstrated the need for further larger-powered studies, and we also found that our 
protocol (with six tDCS sessions for two weeks) may not be the optimal protocol. In addition, 
our results also indicate that tDCS as a therapeutic in Alzheimer’s disease still needs more 
evidence to be considered as an evidence-based intervention.       
 For report II, we applied a novel tDCS protocol, with short intervals between sessions 
(“accelerated tDCS”). We failed to demonstrate that this protocol was efficient for enhancing 
memory. Our results contradict previous recommendations (Nitsche et al., 2015). However, 




tolerated method.           
 In report III, we demonstrated the association between episodic verbal memory 
functions assessed with CVLT-II and the left hippocampus subfield. This finding may support 
CVLT-II as a valuable and reliable tool for assessing verbal memory functions. 
Further research 
There is clearly a need to conduct larger-scale studies to investigate tDCS as a memory 
enhancer. Overcoming recruitment barriers will make it possible to conduct larger studies. 
Further studies will likely benefit from an increasing number of trial sites. A multicenter 
approach may be ideal for obtaining a larger number of healthy participants or patients with 
Alzheimer’s disease (Grill & Karlawish, 2010).      
 Further studies should also apply psychophysiological methods, such as MRI or 
(electroencephalography) EEG, to investigate how tDCS may affect cortical activity and 
neuroplasticity. MRI and/or EEG can be used in combination with memory assessments as 
outcome measures. As Medeiros and colleagues suggest (Medeiros et al., 2012), investigating 
neurobiological effects may be important to optimize tDCS protocols.     
 In addition, further studies should also compare the effects of tDCS with active control 
groups. Currently, most tDCS studies compare the effect of tDCS with placebo tDCS. It could 
be important to determine how tDCS results compare to those of common interventions. For 
instance, comparing active tDCS with anticholinergic drugs in Alzheimer’s disease may be 
one approach. Another possible approach is to compare active tDCS with memory strategies 
(e.g., mnemonics) in healthy participants. For the utility of tDCS, it can be important to 
determine whether tDCS is more or less effective than “treatment as usual” or memory 
strategies. A prime example of a study where tDCS was compared to “treatment as usual” is a 
study by Brunoni and colleagues (Brunoni et al., 2017). In a randomized controlled trial, they 




medication) in patients with depression.        
 As previously noted, individual differences may affect the current distribution of 
current flow to the cortex (Woods et al., 2016). Further studies should use individual 
calibration to overcome the limitations of individual differences. This approach is possible 
through the use of a computer simulation and functional magnetic resonance imaging (Datta 
et al., 2011). Such an approach makes visualization of the spatial distribution possible. 
Furthermore, magnetic resonance imaging can also be helpful for finding the optimal 
electrode placement (Jog et al., 2016). In addition, it makes it possible to determine whether a 
specific tDCS dose and/or duration could alter activation in the targeted area (Bikson, 
Rahman, & Datta, 2012). Such information could permit individual calibration of the tDCS 
protocol.           
 Furthermore, high-definition tDCS (HD-tDCS) should be explored in future studies. 
This approach employs a more focal stimulation by using multiple electrodes (Hampstead, 
Sathian, Bikson, & Stringer, 2017). Typically, the anode is placed in the center, while the 
cathodes are placed around the anode, forming a “ring”. The most common montage is the 4 x 
1 ring montage with a center active electrode surrounded by four return electrodes that is used 
to focus transcranial current within a cortical area of interest circumscribed by the ring 
(Edwards et al., 2013). It was found that such stimulation could be more focal and lead to 
better excitatory effects than the tDCS placement used in this thesis (Kuo et al., 2013). HD-
tDCS is in its infancy but should be investigated in future studies.     
 We should not overlook the fact that Alzheimer’s disease is very complex, and the 
neuropathological mechanisms behind the disease are not fully understood (Querfurth & 
LaFerla, 2010). Less than one percent of all clinical trials have revealed significant results 
(Cummings et al., 2014). Accordingly, our results may reflect the fact that Alzheimer’s 








The main findings in the present thesis merge into three conclusions. These three conclusions 
can be summarized as follows: 
1) Six sessions of active tDCS for 30 minutes delivered over the temporal cortex for two 
weeks did not lead to significantly improved verbal memory functions in Alzheimer’s 
disease patients compared to the results obtained by placebo tDCS. However, a small 
sample size makes it difficult to draw precise conclusions and limits the 
generalizability of the results. No adverse effects were found in this study. 
 
2) Six sessions of active tDCS for 30 minutes over two consecutive days (“accelerated 
tDCS”) delivered over the temporal cortex did not lead to significantly better verbal 
memory functions than placebo accelerated tDCS. No adverse effects were found in 
this study, and tDCS seems to be very well tolerated. 
 
3) Using MRI, it was found that verbal memory functions, assessed with the CVLT-II, 
were significantly associated with the volume of the left hippocampus subfields in 
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Methods: We conducted a randomized, placebo-controlled clinical trial in which tDCS was applied in six 30-minute
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Neuroimaging studies have suggested that Alzheimer’s
disease is associated with pathological and structural
changes in the brain, especially in the temporal cortex
[1]. Several studies have demonstrated that stimulation
of the temporal cortex with transcranial direct current
stimulation (tDCS) can enhance name recall in healthy
elderly persons [2] and improve recognition memory in
patients with Alzheimer’s disease [3–5]. tDCS is non-
invasive and works by inducing a low direct current in
the cortical area of interest [6]. Small electrodes are
placed on the scalp above the brain area that is targeted
by tDCS. This stimulation facilitates cortical excitability
and thereby neuroplasticity [6].
The results of previous studies are promising [3–5].
However, there is still insufficient evidence that supports
tDCS as an intervention for Alzheimer’s disease. Random-
ized, placebo-controlled trials are warranted to assess the
efficacy of temporal cortex tDCS in patients with Alzhei-
mer’s disease. Trials should include more comprehensive
outcome measures to explore the effect of tDCS on mem-
ory function. The aim of the present study was to investi-
gate the effect of tDCS on verbal memory functions in
patients diagnosed with Alzheimer’s disease.
Methods
Study design and participants
A randomized, placebo-controlled trial with a parallel
group design was performed. Two groups were included
in the intervention: an active tDCS group and a placebo
tDCS group. The allocation ratio was 1:1.
Patients diagnosed with Alzheimer’s disease were invited
to participate in the study via a letter from the Department
of Geriatric Medicine at the University Hospital of North
Norway, and healthy participants were recruited through a
newspaper advertisement. The eligibility criteria were living
at home and fulfillment of the research criteria for the
likelihood of having Alzheimer’s disease according to the
revised criteria of the National Institute of Neurological
and Communicative Disorders and Stroke and Alzheimer’s
Disease and Related Disorders Association criteria [7]. We
followed section 4.2 in these criteria: “Probable Alzheimer’s
disease with increased level of certainty.” This determin-
ation of eligibility for the study requires evidence of a
progressive cognitive decline based on information from
informants (relatives) and a cognitive and/or neuro-
psychological evaluation [7].
We excluded patients who scored <18 on the Mini
Mental State Examination (MMSE) [8]. Other exclusion
criteria included serious somatic disorders (cancer, chronic
obstructive pulmonary disease, and heart failure) or neuro-
psychiatric disorders (e.g., severe depression and psychosis)
that might reduce cognitive abilities. The patients with
comorbid cerebral conditions, such as cerebrovascularinjuries and/or stroke, brain tumor, or Parkinson’s disease,
were not eligible to participate in the study. Patients using
cholinesterase inhibitors had to have been using them for
at least 3 months before enrolling in the study. A total of
25 patients with Alzheimer’s disease were included in the
study.
A total of 22 healthy elderly volunteers, aged 59–83
years, served as controls for the neuropsychological test
performance at baseline. None of them had cognitive
impairment or other serious diseases. These healthy
volunteers were recruited through an advertisement. The
control group did not receive any tDCS stimulation. They
completed the Hospital Anxiety and Depression Scale [9],
a questionnaire used to screen for depression and anxiety.
The neuropsychological test battery used for healthy
volunteers and patients with Alzheimer’s disease was
identical. The study was executed in a research laboratory
at the University of Tromsø Institute of Psychology. The
study was ethically approved by the regional committee
for medical and health research ethics (2012/1890) and
was registered in the ClinicalTrials.gov database with the
identifier NCT02518412. All of the patients and healthy
control subjects signed a written informed consent form
in line with the Declaration of Helsinki before participating
in the study. Each patient received a gift card worth 600
NOK (67 EUR, 75 USD) for their participation. Figure 1
contains a flow diagram of the trial.
Outcome measures
The primary outcome measure was verbal memory function.
We used a validated and standardized Norwegian version of
the California Verbal Learning Test–Second Edition (CVLT-
II) to assess three aspects of verbal memory function: imme-
diate recall, delayed recall, and recognition [10]. CVLT-II is
normed by age and gender and is widely used to assess
patients with Alzheimer’s disease [10]. To reduce test-retest
effects, the CVLT-II consists of two parallel versions: the
CVLT-II standard and alternate forms, which contain two
different and independent word lists. We used the standard
form at baseline and the alternative form in the posttest.
The secondary outcome measures included the MMSE,
clock-drawing test, and Trail Making Test parts A and B
(TMT A and B). The MMSE is a screening tool used for
assessing cognitive impairment (e.g., orientation, recall,
arithmetic, language, and ability to follow simple instruc-
tions) [8]. The clock-drawing test is another screening tool
used for detecting cognitive impairment and is also used
to assess visuoconstructive ability [11]. The TMT consists
of part A and part B. TMT A measures sustained atten-
tion, whereas TMT B assesses executive function [12].
To control for general cognitive abilities, we used the
Wechsler Abbreviated Scale of Intelligence with the
matrix reasoning and vocabulary subtests [13]. To screen
for depressive symptoms, we used the Cornell Scale for
Fig. 1 Flow diagram of trial profile
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completed by an informant (i.e., a relative). A score
above 13 indicates depression, which was an exclusion
criterion in the present study. We documented progres-
sive decline using the Informant Questionnaire on Cog-
nitive Decline in the Elderly (IQCODE) [15], which was
also completed by an informant. To assess for potential
confusion during neuropsychological testing, the Confu-
sion Assessment Method [16] was applied by a research
assistant. This questionnaire is based on the observation
of core symptoms of confusion (e.g., inattention, disor-
ganized thinking, and altered level of consciousness).Intervention
The intervention was treatment with tDCS using a direct
current stimulator (neuroConn, Ilmenau, Germany), which
is battery-driven and delivers a direct current. The current
intensity was 2 mA, and the stimulation duration was
30 minutes. A pair of 35-cm2 rubber electrodes transferred
the direct current. These electrodes were inserted into
sponge pads soaked with 10 ml of sterile water. To stimu-
late the left temporal lobe, the anode (positive electrode)
was placed at the T3 position in the 10–20 system for elec-
troencephalographic electrode positioning. The cathode(negative electrode) was placed on the right frontal lobe at
the Fp2 position. For the placebo tDCS, the electrode
placement and session duration were identical to those for
active tDCS. However, in the placebo tDCS, the current
was delivered for 30 seconds at the beginning of the stimu-
lation, then the current was turned off automatically.Randomization and blinding
The patients were assigned to a list with five-digit codes
provided by the manufacturer of the tDCS stimulator.
Each patient had his or her own code. The codes
instructed the stimulator to deliver either placebo or ac-
tive stimulation. The order of the codes was randomized
using the Random.org website (https://www.random.org/).
To ensure double-blinding, the list of code assignments
was not disclosed during the entire tDCS intervention.
The list was decoded when the study was completed to
identify the patients in the active and placebo groups. The
tDCS stimulator did not display information that could be
used to identify the placebo or active stimulation.Procedure
After their inclusion in the study, the patients and their rel-













Fig. 2 Overview of the procedure
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patient completed an informed consent form. Subse-
quently, the patient underwent neuropsychological testing
(baseline). The neuropsychological assessment lasted for
approximately 60 minutes, including several short breaks.
After the neuropsychological assessment was completed,
the first tDCS stimulation commenced. Each patient under-
went six sessions of tDCS or placebo tDCS stimulation for
10 days. Each tDCS stimulation session lasted 30 minutes.
An experienced research assistant administered the tDCS
stimulation. When the last tDCS stimulation was com-
pleted, the patient performed the neuropsychological post-
testing and received a gift certificate. Figure 2 gives an
overview of the procedure.
Power and statistical analyses
In previous studies in which tDCS was used to stimulate
memory functions in patients with Alzheimer’s disease,Table 1 Baseline characteristics
Active tDCS (n = 12) P
Age, years 70.0 (8.0)70.5 (21.0) 7
Males 7 (58 %) 7
DM 12 (100 %) 1
CVLT-II IR 25 (7.9)22.0 (25.0) 2
CVLT-II DR −2.7 (0.5)−2.5 (2.0) −
CVLT-II RG 0.6 (0.9)0.7 (3.0) 1
TMT A 91.0 (45.0)81.0 (138.0) 1
TMT B 266.0 (123.0)215.0 (266.0) 3
Clock 3.33 (1.4)3.5 (5.0) 1
MMSE 20.0 (2.8)21.0 (8.0) 2
WASI Ma 43.0 (9.2)44.5 (27.0) 4
WASI Vo 41.7 (9.3)39.0 (31.0) 4
Cornell Scale for Depression in Dementia 5.7 (4.3)6.0 (12.0) 4
CAM 0.0 0
IQCODE 3.9 (0.3)4.1 (1.2) 4
DM dementia medications, CVLT-II IR California Verbal Learning Test–Second Edition
Delayed Recall, CVLT-II RG California Verbal Learning Test–Second Edition Recognitio
Questionnaire of Cognitive Decline in the Elderly, CAM Confusion Assessment Meth
transcranial direct current stimulation
Data are the mean (SD) or n (%). Median and range are displayed in italic type. The
groups at baseline. The second p value column displays the differences between th
displayed as age- and gender-adjusted z-scores (normalized mean 0, SD 1). For imm
and for recognition the score is an adjusted d′ score (relationship between total hit
Maximum score on the MMSE is 30. Scores <24 indicate cognitive impairment [8]. S
cutoff score on the IQCODE for Alzheimer’s disease is >3.5 [15]. For the Cornell Scal
ranges from 0 to 4, where 0 indicates no symptoms of confusion. The clock-drawin
ap < 0.05 denotes statistically significant valuesresearchers reported significant results (p < 0.05) with a
total of ≤15 patients [3–5] in a within-group design.
Thus, we aimed to include a larger sample than those
described in previous studies [3–5] to ensure accurate
analysis of the effects of the intervention.
We used IBM SPSS version 22 software (IBM, Armonk,
NY, USA) to perform the statistical analysis. Because of a
violation of the assumption of a normal distribution, a
nonparametric Mann-Whitney U test was conducted to
compare the placebo tDCS and active tDCS groups at
baseline. A nonparametric Kruskal-Wallis test was used to
assess the baseline characteristics for all three groups (pla-
cebo tDCS, active tDCS, and healthy control subjects at
baseline).
For the primary analyses, the data had a normal distri-
bution. However, because of a small sample size and a
large variance, we decided to use a nonparametric Mann-
Whitney U test for the analysis. With the Mann-Whitneylacebo tDCS (n = 13) p Value Controls (n = 22) p Value
5.0 (8.7)75.0 (30.0) 0.12 68.8 (6.8)69.0 (24.0) 0.062
(53 %) 0.85 4 (18 %)
2 (92 %) 0.76
3 (6.8)23.0 (22.0) 1.00 52.7 (10.0)54.0 (33.0) 0.01a
2.3 (0.8)−2.5 (2.5) 0.4 −0.4 (0.9)−0.5 (3.5) 0.01a
.0 (0.5)1.1 (1.8) 0.24 1.5 (1.0)2.4 (3.3) 0.01a
43.0 (65.0)131.0 (191.0) 0.059 48.5 (18.6)46.5 (87.0) 0.01a
47.0 (225.0)259.0 (693.0) 0.67 93.0 (34.8)90.5 (149.0) 0 · 01a
.5 (1.6)1.0 (4.0) 0.024a 4.86 (0.86)5.0 (2.0) 0.01a
1.2 (3.9)23.0 (13.0) 0.71 29.5 (1.09)30.0 (5.0) 0.01a
2.5 (6.9)42.0 (26.0) 0.81 58.05 (9.0)61.5 (34.0) 0.01a
1.6 (14.3)44.0 (48.0) 0.76 57.0 (9.9)57.0 (40.0) 0.01a
.8 (3.4)5.0 (12.0) 0.65
.0 1.0
.1 (0.3)4.2 (1.1) 1 · 0
Immediate Recall, CVLT-II DR California Verbal Learning Test–Second Edition
n, WASI Wechsler Abbreviated Scale of Intelligence, IQCODE Informant
od, MMSE Mini Mental State Examination, TMT Trail Making Test, tDCS
first p value column shows the differences between the placebo and active
e active, placebo, and control groups at baseline. For CVLT-II, delayed recall is
ediate recall the score is displayed as a T-score (normalized mean 50, SD 10),
s and false-positive results). For TMT A and B, results are displayed in seconds.
cores on the WASI are displayed as T-scores (normalized mean 50, SD 10). The
e for Depression in Dementia, a cutoff >12 indicates depression [14]. CAM
g test scores range from 0 to 5, where 5 indicates no errors.
Table 2 Outcome measures
Active tDCS (n = 12) Placebo tDCS (n = 13) Difference p Value
Primary outcomes
CVLT-II immediate recall 5.0 (25.0) 0.0 (31.0) 5.0 0.270
CVLT-II delayed recall 0.0 (1.5) 0.0 (2.5) 0.0 0.052
CVLT-II recognition 0.3 (4.0) −0.08 (1.6) 0.47 0.089
Secondary outcomes
MMSE 1.0 (9.0) 1.0 (10.0) 0.0 0.799
Clock-drawing test 0.0 (4.0) 0.0 (5.0) 0.0 0.378
TMT A 3.5 (262.0) −7.0 (219.0) 10.5 0.288
TMT B 22.0 (204.0) −96.0 (443.0) 118.0 0.093
CVLT-II California Verbal Learning Test–Second Edition, MMSE Mini Mental State Examination, TMT Trail Making Test, tDCS transcranial direct current stimulation
Data are the median (range) values. The median values are the estimated change from baseline to posttesting. The positive values indicate positive changes. For
the CVLT-II immediate recall, the median value is displayed as a T-score. For the CVLT-II delayed recall, the median value is displayed as a scaled z-score. For CVLT
recognition, the median value is an adjusted d′ score. The differences between the placebo and active tDCS were calculated using a nonparametric Mann-Whitney
U test
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The raw scores for the neuropsychological tests (CVLT-II
and WASI) were scaled according to standardized norm
tables [13, 17]. The significance level was set at p < 0.05.
Results
A total of 82 patients diagnosed with Alzheimer’s disease
were assessed for eligibility. Of these patients, 45 were ex-
cluded because of comorbid and serious somatic diseases,
MMSE score <17, and psychiatric diseases. A total of 11
patients declined to participate in the study. One patient
decided to withdraw from the study. Twenty-five patients
were enrolled in the study and completed the intervention
between June 2013 and June 2015. Table 1 shows the pa-
tients’ baseline characteristics.
In our analysis, we found significant differences between
healthy control subjects and patients with Alzheimer’s
disease at baseline. Except for the clock-drawing test, there
were no significant differences in the baseline characteris-
tics between the placebo and active groups (Table 1).
For the primary outcome measures, scores between the
active and the placebo group did not differ significantly
on the CVLT-II immediate recall (95 % confidence inter-
val [CI] −9.00 to 2.00; U = 99.00, z-score = 1.14, p =
0.270, r = 0.22), CVLT-II delayed recall (95 % CI −1.0
to 0.0; U = 113.50, z-score = 2.132, p = 0.052, r = 0.42), orTable 3 Frequency table
Active tDCS (n = 12) Placebo tDCS (n = 13)
CVLT-II immediate recall 9 6
CVLT-II delayed recall 4 1
CVLT-II recognition 7 4
CVLT-II California Verbal Learning Test–Second Edition, tDCS transcranial direct
current stimulation
The data represent the number of patients showing improvement on primary
outcome measures. Improvement was displayed as positive changes from
baseline to posttestCVLT-II recognition (95 % CI −1.25 to 0.18; U =
96.00, z-score = 1.38, p = 0.089, r = 0.27). The scores
on the secondary outcome measures (MMSE, clock-
drawing test, and TMT A and B) did not differ
significantly between the active and placebo tDCS
groups (Table 2). Table 3 display the number of pa-
tients showing improvement on primary outcome
measures.
Safety and tolerability
Both patients and their relatives were told to report likely
adverse effects (e.g., headache, itching, skin irritation).
However, no adverse effects were reported, which
indicates that the tDCS intervention was both safe and
well-tolerated.
Discussion
The aim of the present randomized, placebo-controlled
study was to assess the effect of tDCS stimulation on
verbal memory function in patients with Alzheimer’s
disease. We were unable to reveal significant differences
between the placebo and active tDCS groups in both
primary and secondary efficacy outcomes. We found a
tendency for improved delayed recall in the active tDCS
group, albeit not significant.
Boggio and colleagues stimulated [4] the temporal
cortex in patients with Alzheimer’s disease using a 30-
minute tDCS stimulation for 5 consecutive days. This
stimulation increased visual recognition memory scores
by 8.9 %, and the improvement persisted for 1 month
after the last simulation session.
Our results are not in agreement with the results of
previous studies [3–5], which can be attributed to sev-
eral likely explanations. First, we used a fixed stimulation
protocol for all patients. Several recent studies suggested
that anatomical differences (e.g., skull thickness) can
Bystad et al. Alzheimer's Research & Therapy  (2016) 8:13 Page 6 of 7affect current distributions to the cortex [18]. Future
tDCS studies will likely take advantage of computational
models to ensure individual calibration of the stimula-
tion procedure.
Second, the patients in our study may have been less
receptive to tDCS because of the severity of their
disease. tDCS stimulation seems to be less effective in
the advance stages of Alzheimer’s disease [19, 20].
According to our baseline measures of memory function,
a majority of our patients had severe memory impair-
ment (see CVLT-II characteristics in Table 1). Alzhei-
mer’s disease is associated with reduced neuroplasticity
(i.e., a considerable reduction in long-term potentiation)
[21]. This condition is especially pronounced in the tem-
poral cortex [22] and may inhibit the effect of temporal
cortex stimulation when memory impairment is severe.
Third, our study differs from previous studies [3–5] by
its limited sample size and in terms of the stimulation
procedure, study design, and outcome measures. Ac-
cording to Elder and Taylor [23], different stimulation
paradigms should be investigated in Alzheimer’s disease.
The optimal stimulation procedure for Alzheimer’s is
still uncertain. Thus, the present study is in line with
these recommendations and applied a new stimulation
paradigm. Clinical application of tDCS is still in its in-
fancy [24]. It is important to find the most effective
tDCS paradigm for patients with Alzheimer’s disease.
A major difference between the present study and pre-
vious studies [3–5] is our application of standardized
memory assessment. This accords with recommenda-
tions derived from previous reviews [19, 20]. Neuro-
psychological testing is considered to be the most
reliable method for assessing cognitive function in
Alzheimer’s disease [25]. Furthermore, in the present
study, we applied a randomized, placebo-controlled
design. To the best of our knowledge, this is the first
randomized, placebo-controlled study of tDCS stimula-
tion of the temporal cortex in Alzheimer’s disease.
Additionally, none of our patients experienced any ad-
verse effects due to the intervention, which indicates
that tDCS is safe and well-tolerated.
We recommend future studies with outcome measures
that include neuropsychiatric symptoms, neuropsycho-
logical assessment, and activities of daily living. The
Neuropsychiatric Inventory [26] and the Amsterdam In-
strumental Activities of Daily Living Questionnaire [27]
are recommended in that regard.
Large-scale randomized controlled studies are war-
ranted. Recruitment is a main barrier. Recruitment pre-
sents a challenge for clinical studies of tDCS [18] and
trials in Alzheimer’s disease [28]. One way to facilitate
the recruitment process is to increase the number of
trial sites [28]. In addition, increasing the repetition rate
(e.g., stimulation twice per day) could be more feasibleand might require fewer separate days of visits to the
research laboratory. Such stimulation may even prolong
the aftereffects of stimulation [29, 30]. Fewer visits can
be beneficial for recruitment [28].
Conclusions
This randomized, placebo-controlled study failed to
reveal any significant results. There was a nonsignificant
improvement in delayed recall for the active tDCS
condition. This trial showed high tolerability of tDCS. In
future research, investigators should use both neuro-
psychological and neurophysiological outcome measures,
study patients in early stages of Alzheimer’s disease, and
overcome recruitment barriers to increase power.
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The aim of this study was to investigate whether transcranial Direct Current Stimulation 
(tDCS) could improve verbal memory functions in healthy elderly and younger participants. 
We hypothesized that active tDCS led to significantly improved memory function, compared 
to placebo tDCS. Forty healthy participants (20 elderly and 20 younger participants) were 
included in the study. We applied a novel stimulation protocol, where six sessions of anodal 
tDCS were administrated during two consecutive days. Each tDCS session lasted 30 minutes. 
The current intensity was 2mA and the stimulation area was the left temporal lobe at T3 in the 
10-20 EEG system. Immediate recall, delayed recall and recognition memory were assessed 
with California Verbal Learning Test II (CVLT-II) and executive functions were assessed 
with the Trail Making Test (TMT) before the first tDCS session and after the last tDCS 
session. Half of the participants received placebo tDCS, whereas the other half received active 
tDCS. We did not reveal any significant differences between active and placebo tDCS in 
memory functions. However, there was a significant difference between active and placebo 
tDCS in executive function measured by the Trail Making Test (TMT). This experimental 
study failed to reveal significant differences between active and placebo accelerated tDCS for 
verbal memory functions. However, accelerated tDCS was found to be well-tolerated in this 
study.  
Keywords: Memory, transcranial direct current stimulation, neuropsychology, 












































































A method that may improve memory functions in healthy individuals is called transcranial 
direct current stimulation (tDCS) (Manenti, Brambilla, Petesi, Ferrari, & Cotelli, 2013). This 
is a non-invasive stimulation method aimed to enhance plasticity and learning (Prehn & Flöel, 
2015). tDCS treatment is performed by placing two or more electrodes on the scalp (one 
stimulation electrode and one reference electrode). The position of the stimulation electrode 
depends on the cortical area targeted for stimulation. Then, a weak current (2 mA or less) is 
delivered through the stimulation electrode. tDCS is simple to administer and it is associated 
with few adverse effects (Brunoni et al., 2012).      
 tDCS works by modulation of cortical excitability and neuroplasticity (Nitsche & 
Paulus, 2001). Thus, tDCS aims to increase neuroplasticity through the process of long-term 
potentiation (LTP) (Monte-Silva et al., 2013). This involves an increase in synaptic strength 
and is crucial for neuroplasticity and memory (Lynch, 2004). tDCS does not directly cause 
neuronal firing, but trigger conditions that makes neuronal firing more likely (Reinhart, 
Cosman, Fukuda, & Woodman, 2017).        
 Previous studies suggest that tDCS may enhance memory functions (Kristin Prehn & 
Flöel, 2015). For instance, Sandrini and colleagues (Sandrini et al., 2014) found that a 15 
minute active tDCS session could significantly improve recall of a wordlist after 30 days. 
Furthermore, another study found that tDCS could improve verbal memory functions in both 
old and young participants (Manenti et al., 2013). Prehn and colleagues found that a 
combination of selective serotonin reuptake inhibitor (SSRI) and tDCS could give significant 
better immediate memory in both younger and older participants (Prehn et al., 2017). 
However, no such effects were found for delayed recall.       
 Verbal memory functions decline with age (Cargin, Maruff, Collie, Shafiq-Antonacci, 
& Masters, 2007). Thus, it could be assumed that aging can affect the efficacy of tDCS, when 
tDCS is used as a memory enhancer. For instance, Ross and colleagues found that tDCS 
stimulation of the temporal lobe could improve name recall for faces in both younger and 
older participants (Ross, McCoy, Coslett, Olson, & Wolk, 2011). However, older participants 
improved more compared to younger participants. One assumption is that that aging weakens 
cortical connections and that tDCS may enhance neuronal firing in a higher degree than for 
younger participants (Gutchess, 2014). tDCS may work better for elderly, since younger 
individuals have a nearly optimal level of neuroplasticity and thus smaller potential for 


































































2018) found that younger participants improved more than older participants and that older 
participants may be less receptive to tDCS. It is uncertain whether older participants benefits 
more from tDCS than younger participants. Hence, there is a need to investigate if the effect 
of tDCS differs between elderly and younger individuals.      
 It is also found that tDCS can improve memory functions in patients with Alzheimer`s 
disease. Boggio and colleagues (2012) found that 30 minute sessions of active tDCS for five 
consecutive days could lead to a nearly 10 % improvement in recognition memory. This 
improvement was prolonged for one month and was significantly higher in patients who 
underwent tDCS than in those who received placebo tDCS, which only led to a 2.6 % 
improvement.           
 On the other hand, Bystad and colleagues (2016a) found no significant differences in 
memory improvement between active and placebo tDCS in patients with Alzheimer`s disease. 
In Alzheimer`s disease, studies using tDCS have shown inconsistent results (Kim, 2016). In 
healthy individuals, tDCS is also associated with mixed results (Tremblay et al., 2014).  
 Before tDCS can be validated as a therapeutic tool, it is important to investigate 
different stimulation protocols in healthy individuals, in order to find the optimal stimulation 
protocol. In addition, since cognitive functions are relevant for our function in daily life it can 
be useful to investigate if tDCS leads to cognitive improvement.    
 The optimal number of tDCS sessions and the interval between sessions remain 
uncertain (Woods et al., 2016). For both experimental and clinical application of tDCS, the 
lack of standardized protocols possesses a problem when conducting new studies or 
comparing results between studies (Cappon, Jahanshahi, & Bisiacchi, 2016).   
 It is assumed that a high repetition rate, with short intervals between each tDCS 
sessions can probably be more efficient than increasing the duration of the stimulation 
(Nitsche, Kuo, Paulus, & Antal, 2015; Woods et al., 2016). Such high repetition rate may lead 
to longer lasting effects, since the neurophysiological after-effects of tDCS is relatively short 
lived. For instance, a recent study suggested that 13 minutes of tDCS stimulations of 2mA 
leads to 90 minutes after-effect (Thair, Holloway, Newport, & Smith, 2017).   
 To prolong the effect of tDCS, it has been proposed to use short intervals (< 30 
minutes) between sessions (Woods et al., 2016). Such short intervals between each session 
can be referred to as “accelerated tDCS” (Bystad, Rasmussen, Abeler, & Aslaksen, 2016). A 
previous case study found that such application of tDCS could improve memory functions in 
patients with early stage Alzheimer`s disease (Bystad et al., 2016b). However, to date, this 


































































 Based on previous studies (Manenti et al., 2013; Sandrini et al., 2014), we aimed to 
investigate the effect of accelerated tDCS on memory functions and executive functions in 
both healthy elderly and healthy younger participants. We applied an accelerated tDCS 
protocol, with short (30 minutes) intervals between each session. We hypothesized that active 
tDCS would lead to a significantly improved verbal memory function (immediate recall, 
delayed recall and recognition), compared to placebo tDCS.  
Materials and methods 
Participants                            
A total of 40 individuals participated in the study. There were 20 elderly (59-69 years, mean 
age = 63 years, 16 females) and 20 young (19-30 years, mean age = 22 years, 13 females) 
participants. The eligibility criteria were absence of any serious somatic or psychiatric 
conditions or injuries to the central nervous system that could impact cognitive functions. 
Such conditions included cancer, cerebrovascular diseases, chronic obstructive pulmonary 
disease, heart failure, depression / anxiety and psychosis. All participants completed the 
Hospital Anxiety and Depression Scale (HADS) (Mykletun, Stordal, & Dahl, 2001), a 
questionnaire used to screen for depression and anxiety. Patients with scores above 15 on the 
HADS were excluded because depression may affect cognitive functions (Lam, Kennedy, 
McIntyre, & Khullar, 2014).         
 Participants were recruited by advertisement. All participants were informed that the 
experiment aimed to investigate if tDCS could improve memory functions. The study was 
executed in a research laboratory at the University of Tromsø, Department of Psychology. All 
participants signed a written informed consent prior to participation. They were compensated 
with a gift-card, worth 500 NOK (approximately 59 USD) after the participation. The study 
was approved by the Regional Ethical Committee for Research Ethics in Medicine and Health 
Sciences (2012/1890).   
Outcome measures 
In the present study, the primary outcome measure was verbal memory functions, assessed 
with the California Verbal Learning Test–Second Edition (CVLT-II) (Delis, Kramer, Kaplan, 
& Ober, 2004). The CVLT-II is a standardized neuropsychological test, normalized by age 
and gender. The CVLT-II assess immediate recall, delayed recall and recognition. The CVLT-
II is widely used (Delis et al., 2004) and based on list-recall, where the participant is 


































































al., 2004). To reduce test-retest practice effects, we used the standard version at baseline, and 
the alternative form after the last tDCS session. The standard and alternative forms have 
different word-lists.           
 The secondary outcome measures included the Trail Making Test A and B (TMT A 
and TMT B) (Tombaugh, 2004) and the Digit Span test from the Wechsler Memory Scale 
(WMS) (Wechsler, 1998). TMT A measures sustained attention, speed and motor function, 
whereas TMT B also assesses executive functions. WMS Digit Span measures attention / 
working memory. The participant is instructed to repeat a cumulative sequence of numbers 
forward and backward.          
 To control for general cognitive abilities, the Matrix Reasoning and Vocabulary tests  
from the Wechsler Abbreviated Scale of Intelligence (WASI) (Pearson, 1999) were conducted 
at baseline. To screen for cognitive impairment among the elderly participants we used the 
Mini Mental Status Evaluation (MMSE-NR) (Folstein, Folstein, & McHugh, 1975).  
 To assess possible adverse effects, we used a questionnaire from Brunoni and 
colleagues that was translated into Norwegian (Brunoni et al., 2011). This questionnaire asks 
specifically about adverse effects from the tDCS procedure, specifically regarding itching, 
tingling, headache and discomfort (Brunoni et al., 2011).  
Transcranial Direct Current Stimulation (tDCS) 
The stimulation was delivered using a direct current stimulator (neuroConn, Ilmenau, 
Germany). The stimulation duration was 30 minutes and the current intensity was 2mA. The 
current was transferred to the skull through a pair of 35-cm2 rubber electrodes. The anode 
(stimulation electrode) was placed at the T3 position in the 10-20 system (a system used for 
electroencephalographic electrode positioning). The cathode (reference electrode) was placed 
at the Fp2 position, i.e on the right frontal lobe. For both the placebo and the active tDCS, the 
electrode placement and session duration were similar. In the placebo tDCS, a current was 
delivered only for the first 30 seconds. After these 30 seconds, the stimulator turned the 
current off automatically.           
 All participants were assigned their own five-digit code. This code determined if the 
tDCS device should give the placebo or active stimulation. Neither the experimenter nor the 
participant knew if the tDCS stimulator delivered the active or placebo stimulation. Thus, the 
study was double blind. The order of the codes was randomized using the Random.org 




































































Participants met individually for two consecutive days in a research laboratory at the 
university. First, each participant received information about the study. Then, the participant 
underwent the neuropsychological assessment. The duration of this assessment was 
approximately 60 minutes. When the assessment was completed, the first tDCS session began. 
Three sessions were given on both the first day and the second day. Each tDCS session lasted 
for 30 minutes. The break between the sessions was about 30 minutes. After the final tDCS 
session, the participant underwent neuropsychological assessment. See figure 1 for an 
overview of the procedure.  
Figure 1:  
 
 
Statistical and power analysis 
All data were analyzed in SPSS Version 22. We calculated the change scores between 
baseline and post stimulation neuropsychological assessment scores to investigate the effect 


































































the mean change of scores between placebo and active tDCS. A MANOVA was conducted to 
investigate group differences between placebo and active tDCS adjusted for age. Data were 
normally distributed, shown by Shapiro Wilk test.       
 A previous study (Sandrini et al., 2014) with healthy participants found that active 
tDCS led to significant improvement in verbal memory functions, compared to placebo tDCS. 
In that study, tDCS was delivered only once, with a 15-minute duration. Based on mean 
scores from Sandrini et al., 2014, we used a power estimation calculator (clincalc.com) and 
estimated that our study had 80 % power in order to achieve a significant effect with a least 
32 participants (16 placebo and 16 active tDCS). Thus, we wanted to include a total of 40 
participants. The alpha-level was 0.05.   
Results 
Table 1 displays the number of participants who improved on different outcome scores from 
baseline to post-test. The analysis showed no significant differences in CVLT-II scores 
between the active and the placebo tDCS (Table 2). For CVLT-II immediate recall F = 0.067, 
df = (1.0), p = 0.79, CVLT-II delayed recall (F = 0.24, df = (1.0), p = 0,62) and CVLT-II 
recognition (F = 0.092, df = (1.0), p = 0.76), no significant differences were found between 
the active and the placebo tDCS. However, we found that the active group scored 
significantly better on change scores than the placebo group on TMT-B, F = 4.54, df = (1.0), p 
= 0.040.  
 
Table 1. Frequency table  
 Active tDCS  
(N = 20) 
Placebo tDCS 
(N =20) 
CVLT-II immediate recall 9 6 













The data represent the number of patients who showed improvements (>) on the outcome measures.                       
Improvement was considered as improved scores from baseline to the post-test.    
 
Table 2. Changes in cognitive scores for all participants (N = 40) 
  
Group Age Group  












































































      
CVLT delayed 0.622 0.24 0.092 3.00 0.46 0.544 
      
CVLT recogntion  0.20 0.092 0.535 0.39 0.61 0.25 
      
TMT-A 0.91 3.02 0.59 3.81 0.93 0.007 
      
TMT-B 0.040 4.54   0.66 0.18 0.97 0.33 
      
Digit Span 0.365 0.84 0.78 0.77 0.81 0.055 
      
Note: “Group” is active or placebo, “Age Group” is younger or elderly and “Age Group * Group” is                                        
the interaction between the group and the age group.       
 
For the group of elderly participants, we found no differences in the CVLT-II scores between 
active and placebo tDCS (see Table 3). For CVLT-II immediate recall (t(15.69) = - 0.90, p = 
0.37), CVLT-II delayed recall (t(14.83) = 0.18 p = 0.85) and CVLT-II recognition (t(11.19) = 
0.43, p = 0.67), no significant difference were found between active and placebo tDCS. For 
TMT A (t(17.94) = 2.02, p = 0.058) and TMT B (t(15.92) = 0.64 , p = 0.52), and Digit Span 
(t(12.45) = - 0.98, p = 0.91), there was no significant difference between active and placebo 
group.  
 




Deviation P value 
 
Hedges g 
CVLT immediate Placebo -4.90 10.98 0.37 0.38 
Active -1.10 7.34   
CVLT delayed Placebo -0.35 0.97 0.85 0.07 
Active -0.43 1.01   
CVLT recognition Placebo -0.25 0.58 0.67 0.18 
Active -0.44 1.23   
TMT-A Placebo -2.10 7.50 0.058 0.86 
Active -9.10 7.93   
TMT-B Placebo -13.80 28.05 0.52 0.28 
Active -21.25 20.66   
Digit Span  Placebo 10,20 1,47 0,91 0.04 
Active 10,10 2,51   
Note: The mean values are the estimated change from baseline to post-testing (post testing minus baseline). For the 
CVLT-II immediate recall score, the mean value is displayed as a T-score. For the CVLT-II delayed recall and 
recognition scores, the mean value are displayed as Z-scores. An independent t-test was applied to calculate the 
differences between the placebo and active tDCS groups. For the CVLT scores and Digit Span scores, a positive 
values indicates a positive change. For TMT A and B, negative values indicate improvements. Significant values (p 




































































For the group of younger participants, we found no difference in CVLT-II scores between 
active and placebo tDCS (see Table 4). For CVLT-II immediate recall (t(18.00) = 0.22 , p = 
0.82), CVLT-II delayed recall (t(17.69) = - 0.82, p = 0.42) and CVLT-II recognition (t(17.82) 
= - 0.58, p = 0.56), no significant difference were found between active and placebo tDCS. 
For TMT-A (t(17.99) = 1.08, p = 0.29 and Digit Span (t(16.90) = - 0.48, p = 0.63) there were 
no significant differences between the active and placebo groups. However, on TMT-B 




Table 4. Changes in scores for younger participants (N = 20) 
 
Outcome Group  Mean 
Std. 
Deviation P value 
 
Hedges g 
CVLT immediate Placebo -4.30 9.80 0.82 0.09 
Active -5.30 9.83   
CVLT delayed Placebo -1.25 1.29 0.42 0.35 
Active -0.80 1.13   
CVLT recognition  Placebo -0.60 0.90 0.56 0.26 
Active -0.35 1.00   
TMT-A Placebo -8.00 9.92 0.29 0.46 
Active -12.80 9.79   
TMT-B Placebo -10.20 6.90 0.007* 1.39 
Active -30.50 18.43   
Digit Span Placebo 0.50 2.06 0.63 0.20 
Active 0.90 1.59   
 
Adverse-effects 
No adverse-effects were reported, neither in young participants or elderly participants, based 
on a questionnaire (Brunoni et al., 2011) for adverse-effects in tDCS procedures.   
 
Discussion 
The aim of the present study was to investigate whether accelerated tDCS could improve 
verbal memory functions in healthy young and healthy elderly participants. We also 
investigated whether tDCS could affect executive functions in both young and elderly 
participants. In addition, we wanted to study if age was a significant factor of tDCS efficacy. 
 We did not reveal significant differences between placebo and active tDCS in verbal 


































































al., 2013; Sandrini et al., 2014). Furthermore, we did not find any significant differences in 
verbal memory between placebo and active tDCS, whilst adjusting for age.  
 However, we found a significant difference between placebo and active tDCS for 
executive functions, as measured with TMT-B. This significant difference was only found 
among the younger participants. It should be noted that none of our participants reported any 
adverse-effects, despite the short intervals between each the tDCS sessions. Accelerated tDCS 
seems to be both safe and well-tolerated in our study.      
 The reason for our non-significant effect of tDCS on verbal memory functions may be 
attributed to several different causes. First, we applied a novel stimulation protocol (i.e., 
accelerated tDCS, with short intervals between each session). To our knowledge, no studies 
have investigated such an intensive protocol. Accelerated tDCS is based on recommendations 
from Nitsche and colleagues (2015), rather than evidence. This protocol may not be as 
efficient as we expected.           
 Second, it also uncertain if tDCS actually leads to cognitive (Horvath, Forte, & Carter, 
2015b) and neurophysiological (Horvath, Forte, & Carter, 2015a) changes in healthy 
individuals. Horvath and colleagues argue that tDCS has some major shortcomings (e.g., 
electric current influences, inter-subject variability) (Horvath, Carter, & Forte, 2014). For 
instance, Trembley (Tremblay et al., 2014) reported that one participant experienced a 251 % 
increase in motor evoked potentials, whereas another participant experienced a 41 % 
decrease. Anatomic differences (e.g skull thickness) and neurophysiology are individual 
factors that may affect the distribution of current flow to the cortex (Horvath et al., 2014). The 
effect of tDCS on cognitive function in healthy participants is associated with conflicting 
results (Tremblay et al., 2014). Hsu and colleagues (2015) argues that tDCS may work best in 
pathological states and benefit those who need it most, since there may be a ceiling effect in 
healthy participants and tDCS may serve to strength weaken pathological neural circuits. 
Consequently, we cannot disregard a lack of effect from our tDCS stimulation.  
 We revealed a significant effect on executive functions in the young participants. A 
possible explanation is the limitation of the TMT-B test, which was used to measure executive 
functions. TMT-B seems to have substantial test-retest practice effects, especially over a short 
interval (Bartels, Wegrzyn, Wiedl, Ackermann, & Ehrenreich, 2010). For instance, a study 
(Bartels et al., 2010) found that retest with TMT-B after three weeks could improve the score 
with nearly 10 seconds. Since memory test usually have parallel versions, TMT-A and TMT-
B are more susceptible to test-retest practice effects. According to our results (Table 1), most 


































































completely rule out a test-retest practice effect.      
 Further, tDCS has low specificity (Csifcsak, Boayue, Puonti, Thielscher, & Mittner, 
2018). Even if our aim was to stimulate temporal cortex, other cortical areas may also have 
been affected (e.g frontal cortex), since tDCS may lead to a widespread alterations of 
functional connectivity (Keeser et al., 2011). It is suggested that tDCS may enhance alerting 
attention (Coffman, Trumbo, & Clark, 2012). This could lead to better scores on TMT-B. 
        
Limitations 
The present study has several limitations that needs to be addressed. One limitation is that we 
relied solely on cognitive functions for our outcome measures. Consequently, we do not know 
if the tDCS stimulation induced any neurophysiological changes. There may be a chance that 
our tDCS protocol affected neuroplasticity and neural activity. However, this remains 
unknown in our study.          
 Further, a second limitation is our “one size fits all” approach. It is reasonable to 
assume that anatomical differences (e.g., skull thickness) can affect the efficacy of the tDCS 
stimulation, i.e how the current is distributed to the cortex. We did not apply a computational 
model to calibrate the tDCS stimulation for each participant. Our lack of individual 
calibration is a limitation, since individual differences can be an important factor (Sarkar, 
Dowker, & Cohen Kadosh, 2014).        
 A third limitation is that we did not combine tDCS with any cognitive stimulation. We 
only applied tDCS. This could affect the efficacy of our tDCS protocol, since the effect of 
tDCS may improve when tDCS and cognitive stimulation are used simultaneously (Hsu et al., 
2015).  
Future research  
Further research should take advantage of both neuropsychological assessment and 
psychophysiological measures (e.g., event-related potentials or neuroimaging). A combination 
of such outcome measures will provide insight into the cognitive and neurophysiological 
effect of tDCS. There is clearly a need to investigate the potential effect of tDCS on 
neurobiological changes in healthy individuals. For future research, it can also be useful to 
calibrate the tDCS procedure for each participant. A computation model can be applied in 


































































addition, it could be of potential interest to study the effect when tDCS and cognitive 
stimulation are delivered simultaneously.    
Conclusions 
This experimental study did not reveal a significant difference between active and placebo 
accelerated tDCS for verbal memory functions. However, we found that the tDCS stimulation 
led to a significant improvement in executive function in younger participants, assessed with 
TMT-B. Our accelerated tDCS protocol, with short intervals between each session, was well 
tolerated with no side effects of the stimulation. Future research should combine 
neuropsychological and neurophysiological outcome measures.  
Acknowledgments                                         
We thank all of the healthy younger and healthy elderly persons who participated in this 
study.  
List of abbreviations  
tDCS = transcranial Direct Current Stimulation                              
CVLT-II = California Verbal Learning Test II                     
TMT = Trail Making Test                             
MMSE = Mini Mental Status Examination           
HADS = Hospital Anxiety and Depression Scale                                
WASI= Wechsler Abbreviated Scale of Intelligence.                         
WMS = Wechsler Memory Scale  
Contributors                                
M.B. planned the study, recruited patients, collected the data, wrote the first draft, revised and 
reviewed the final draft and analyzed the data. He is the corresponding author. O.G drafted 
and revised the manuscript. I.D.R. drafted and revised the manuscript. N.G, B.S, I.L.W, and 
L.N collected the data. P.M.A. planned the study, wrote the first draft, revised the manuscript, 
analyzed the data and revised the final manuscript. He served as a supervisor for M.B. All 
authors approved the final manuscript. 
Potential conflicts of interest                          


































































Funding source                                   
The study was funded by a PhD project from the Department of Psychology, University of 





 References  
 
1. Bartels, C., Wegrzyn, M., Wiedl, A., Ackermann, V., & Ehrenreich, H. (2010). 
Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive 
testing. BMC Neuroscience, 11(1), 118. doi:10.1186/1471-2202-11-118 
2. Boggio, P. S., Ferrucci, R., Mameli, F., Martins, D., Martins, O., Vergari, M., & al., e. 
(2012). Prolonged visual memory enhancement after direct current stimulation in 
Alzheimer's disease. Brain stimulation, 5(3), 223-230.  
3. Brunoni, A. R., Amadera, J., Berbel, B., Volz, M. S., Rizzero, B. G., & Fregni, F. 
(2011). A systematic review on reporting and assessment of adverse effects associated 
with transcranial direct current stimulation International Journal of 
Neuropsychopharmacology 14, 1133-1145.  
4. Brunoni, A. R., Nitsche, M. A., Bolognini, N., Bikson, M., Wagner, T., Merabet, L., . . 
. Fregni, F. (2012). Clinical research with transcranial direct current stimulation 
(tDCS): Challenges and future directions. Brain stimulation, 5(3), 175-195. 
doi:10.1016/j.brs.2011.03.002 
5. Bystad, M., Grønli, O., Rasmussen, I. D., Gundersen, N., Nordvang, L., Wang-
Iversen, H., & Aslaksen, P. M. (2016). Transcranial direct current stimulation as a 
memory enhancer in patients with Alzheimer’s disease: a randomized, placebo-
controlled trial. Alzheimer's research & therapy, 8(1), 1.  
6. Bystad, M., Rasmussen, I. D., Abeler, K., & Aslaksen, P. M. (2016). Accelerated 
Transcranial Direct Current Stimulation in Alzheimer's Disease: A Case Study. Brain 


































































7. Cappon, D., Jahanshahi, M., & Bisiacchi, P. (2016). Value and Efficacy of 
Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical 
Review Since 2000. Frontiers in Neuroscience, 10, 157. 
doi:10.3389/fnins.2016.00157 
8. Cargin, J. W., Maruff, P., Collie, A., Shafiq-Antonacci, R., & Masters, C. (2007). 
Decline in verbal memory in non-demented older adults. Journal of Clinical & 
Experimental Neuropsychology, 29(7), 706-718. doi:10.1080/13825580600954256 
9. Coffman, B. A., Trumbo, M. C., & Clark, V. P. (2012). Enhancement of object 
detection with transcranial direct current stimulation is associated with increased 
attention. BMC Neuroscience, 13, 108. doi:10.1186/1471-2202-13-108 
10. Csifcsak, G., Boayue, N. M., Puonti, O., Thielscher, A., & Mittner, M. (2018). Effects 
of transcranial direct current stimulation for treating depression: A modeling study. 
Journal of Affective Disorder, 234, 164-173. doi:10.1016/j.jad.2018.02.077 
11. Delis, D. H., Kramer, J. H., Kaplan, B., A, & Ober, B. A. (2004). California Verbal 
Learning Test – Second edition (CVLT-II). Stockholm: Pearson  
12. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state". A 
practical method for grading the cognitive state of patients for the clinician. Journal of 
Psychiatric Research, 12(3), 189-198.  
13. Gutchess, A. (2014). Plasticity of the aging brain: New directions in cognitive 
neuroscience. Science, 346, 279-582.  
14. Horvath, J. C., Carter, O., & Forte, J. D. (2014). Transcranial direct current 
stimulation: five important issues we aren't discussing (but probably should be). 
Frontiers in Systems Neuroscience, 8, 2. doi:10.3389/fnsys.2014.00002 
15. Horvath, J. C., Forte, J. D., & Carter, O. (2015a). Evidence that transcranial direct 
current stimulation (tDCS) generates little-to-no reliable neurophysiologic effect 
beyond MEP amplitude modulation in healthy human subjects: a systematic review. 
Neuropsychologia, 66, 213-236.  
16. Horvath, J. C., Forte, J. D., & Carter, O. (2015b). Quantitative review finds no 
evidence of cognitive effects in healthy populations from single-session transcranial 
direct current stimulation (tDCS). Brain stimulation, 8(3):535-550. 
17. Hsu, W. Y., Ku, Y., Zanto, T. P., & Gazzaley, A. (2015). Effects of noninvasive brain 
stimulation on cognitive function in healthy aging and Alzheimer's disease: A 



































































18. Keeser, D., Meindl, T., Bor, J., Palm, U., Pogarell, O., Mulert, C., . . . Padberg, F. 
(2011). Prefrontal transcranial direct current stimulation changes connectivity of 
resting-state networks during fMRI. Journal of Neuroscience, 31(43), 15284-15293. 
doi:10.1523/jneurosci.0542-11.2011 
19. Kim, Y. J. (2016). Transcranial Direct Current Stimulation as an Alternative 
Treatment in Patients with Alzheimer's Disease. Brain & Neurorehabilitation, 10(1).  
20. Lam, R. W., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014). Cognitive 
Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and 
Implications for Treatment. Canadian Journal of Psychiatry. Revue Canadienne de 
Psychiatrie, 59(12), 649-654.  
21. Leach, R. C., McCurdy, M. P., Trumbo, M. C., Matzen, L. E., & Leshikar, E. D. 
(2018). Differential Age Effects of Transcranial Direct Current Stimulation on 
Associative Memory. J Gerontol B Psychol Sci Soc Sci. doi:10.1093/geronb/gby003 
22. Lynch, M. A. (2004). Long-term potentiation and memory. Physiological Review, 
84(1), 87-136. doi:10.1152/physrev.00014.2003 
23. Manenti, R., Brambilla, M., Petesi, M., Ferrari, C., & Cotelli, M. (2013). Enhancing 
verbal episodic memory in older and young subjects after non-invasive brain 
stimulation. Frontiers of Aging Neuroscience, 5, 49. doi:10.3389/fnagi.2013.00049 
24. Monte-Silva, K., Kuo, M. F., Hessenthaler, S., Fresnoza, S., Liebetanz, D., Paulus, 
W., & Nitsche, M. A. (2013). Induction of late LTP-like plasticity in the human motor 
cortex by repeated non-invasive brain stimulation. Brain Stimulation, 6(3), 424-432. 
doi:10.1016/j.brs.2012.04.011 
25. Mykletun, A., Stordal, E., & Dahl, A. A. (2001). Hospital Anxiety and Depression 
(HAD) scale: Factor structure, item analyses and internal consistency in a large 
population. British Journal of Psychiatry, 179(12), 540-544.  
26. Nitsche, M. A., Kuo, M.-F., Paulus, W., & Antal, A. (2015). Transcranial Direct 
Current Stimulation: Protocols and Physiological Mechanisms of Action. In: Textbook 
of Neuromodulation (pp. 101-111): New York: Springer. 
27. Nitsche, M. A., & Paulus, W. (2001). Sustained excitability elevations induced by 
transcranial DC motor cortex stimulation in humans. Neurology, 57(10), 1899-1901.  
28. Pearson. (1999). WASI Manual; Wechsler Abbreviated Scale of Intelligence Manual. 


































































29. Prehn, K., & Flöel, A. (2015). Potentials and limits to enhance cognitive functions in 
healthy and pathological aging by tDCS. Frontiers in Cellular Neuroscience, 9, 355. 
doi:10.3389/fncel.2015.00355 
30. Prehn, K., Stengl, H., Grittner, U., Kosiolek, R., Olschlager, A., Weidemann, A., & 
Floel, A. (2017). Effects of Anodal Transcranial Direct Current Stimulation and 
Serotonergic Enhancement on Memory Performance in Young and Older Adults. 
Neuropsychopharmacology, 42(2), 551-561. doi:10.1038/npp.2016.170 
31. Reinhart, R. M. G., Cosman, J. D., Fukuda, K., & Woodman, G. F. (2017). Using 
transcranial direct-current stimulation (tDCS) to understand cognitive processing. 
Attention, Perception & Psychophysics, 79(1), 3-23. doi:10.3758/s13414-016-1224-2 
32. Ross, L. A., McCoy, D., Coslett, H. B., Olson, I. R., & Wolk, D. A. (2011). Improved 
proper name recall in aging after electrical stimulation of the anterior temporal lobes. 
Frontiers in aging neuroscience, 3(10), 1-8. doi:10.3389/fnagi.2011.00016 
33. Sandrini, M., Brambilla, M., Manenti, R., Rosini, S., Cohen, L. G., & Cotelli, M. 
(2014). Noninvasive stimulation of prefrontal cortex strengthens existing episodic 
memories and reduces forgetting in the elderly. Frontiers in aging neuroscience, 6, 
289. doi:10.3389/fnagi.2014.00289 
34. Sarkar, A., Dowker, A., & Cohen Kadosh, R. (2014). Cognitive Enhancement or 
Cognitive Cost: Trait-Specific Outcomes of Brain Stimulation in the Case of 
Mathematics Anxiety. The Journal of Neuroscience, 34(50), 16605.  
35. Thair, H., Holloway, A. L., Newport, R., & Smith, A. D. (2017). Transcranial Direct 
Current Stimulation (tDCS): A Beginner's Guide for Design and Implementation. 
Frontiers in Neuroscience, 11(641). doi:10.3389/fnins.2017.00641 
36. Tombaugh, T. N. (2004). Trail Making Test A and B: Normative data stratified by age 
and education. Archives of Clinical Neuropsychology, 19(2), 203-214.  
37. Tremblay, S., Lepage, J.-F., Latulipe-Loiselle, A., Fregni, F., Pascual-Leone, A., & 
Théoret, H. (2014). The uncertain outcome of prefrontal tDCS. Brain stimulation, 
7(6), 773-783. doi:10.1016/j.brs.2014.10.003 
38. Wechsler, D. (1998). Wechsler Memory Scale - 3rd edition (WMS-III). Harcourt, TX: 
The Psychological Corporation. 
39. Woods, A. J., Antal, A., Bikson, M., Boggio, P. S., Brunoni, A. R., Celnik, P., . . . 
Nitsche, M. A. (2016). A technical guide to tDCS, and related non-invasive brain 









































































































































Aslaksen, P.M., Bystad, M., Ørbo, M.C. & Vangberg, T.R. (2018). The relation of hippocampal 
subfield volumes to verbal episodic memory measured by California Verbal Learning Test II in 
healthy adults. Behavioral Brain Research, 351, 131-137. 




The relation of hippocampal subfield volumes to verbal episodic memory
measured by the California Verbal Learning Test II in healthy adults
Per M. Aslaksena,b,⁎, Martin K. Bystada, Marte C. Ørboc, Torgil R. Vangbergd
a Department of Psychology, The Arctic University of Tromsø UiT, Tromsø, Norway
bDepartment of Child and Adolescent Psychiatry, The Regional Unit for Eating Disorders, The University Hospital of North Norway, Tromsø, Norway
c Department of Cardiothoracic and Vascular Surgery, Heart and Lung Clinic, The University Hospital of North Norway, Tromsø, Norway
d Department of Radiology, University Hospital of North Norway, Tromsø, Norway




California Verbal Learning Test
FreeSurfer
Healthy volunteers
A B S T R A C T
Total hippocampal volume has previously been shown to correlate with performance on tests for verbal episodic
memory. However, there are sparse evidence on how hippocampal subfield volumes are related to verbal epi-
sodic memory in healthy adults. The present study investigated the association between volumes of separate
hippocampal subfields and verbal episodic memory performance in healthy volunteers. Forty-seven participants
(31 females) between 20–71 years age underwent testing with the California Verbal Learning Test II (CVLT II),
and the Wechsler Abbreviated Scale of Intelligence (WASI) to obtain an estimate of cognitive functioning. T1-
weighted MR images were obtained after cognitive testing, and volumetric estimates adjusted for age and es-
timated total intracranial volume were calculated in the FreeSurfer 6.0 software suite for cerebral -and hippo-
campal structures. The sample performed within the statistical normal range on both CVLT II and WASI.
Significant correlations adjusted for multiple testing were found between CVLT II subtests of total learning, free
immediate recall and free delayed recall and volumes of the left Cornu Ammonis (CA) 1–4 subfields. There were
no significant correlations between right hippocampal subfields and CVLT II performance, and no significant
correlation between WASI results and hippocampal subfields. The present results suggest that better verbal
episodic memory measured by the CVLT II is associated with relative larger volumes of specific left CA hip-
pocampal subfields in healthy adults. Due to the small sample size and large age-span of the participants, the
present findings are preliminary and should be confirmed in larger samples.
1. Introduction
Episodic memory, which is the ability to remember experiences that
occurred at a particular place and time, has been related to hippo-
campal functions in several studies [1–3]. The hippocampus is usually
subdivided into the Cornu Ammonis (CA) CA1, CA2-3, CA4/dentate
gyrus, the presubiculum and the subiculum, which are the larger sub-
structures of the hippocampus. Previous studies have suggested that
these subfields have separate and specialized functions with regard to
memory processes, and the subfield division are therefore not merely an
anatomical classification [4,5].
Development of advanced magnet resonance imaging (MRI) tech-
niques during the last decades have provided the opportunity to study
both anatomical features and cerebral activation with high precision.
Volumetric MRI studies that combines structural assessment of the
brain with concomitant cognitive measures provides the opportunity to
study the inter-individual variability in brain structures that can be
statistically related to certain categories of cognition [6]. The structural
approach is useful when assessing whether structural individual dif-
ferences in cerebral areas are associated with normal or impaired
cognition [7].
The volume of the hippocampal subfields is assumed to be positively
correlated with episodic memory functioning [8,9], even if some stu-
dies have reported a negative association between hippocampal volume
and memory processes [10,11]. However, most previous volumetric
studies of verbal memory and hippocampal size have used data for the
hippocampus without separating the subfields and the number of stu-
dies investigating the relation between hippocampal subfields and
cognitive functions are sparse. Furthermore, the results in the existing
studies are not entirely consistent, and differences in findings may arise
from differences in characteristics of the samples, method for esti-
mating hippocampal subfields and selection of cognitive tests.
A recent study using subfield segmentation of MRI data from
healthy elderly showed that verbal memory performance measured by
https://doi.org/10.1016/j.bbr.2018.06.008
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the Repeatable Battery for Assessment of Neuropsychological status
(RBANS) shows that larger volumes of the CA1 and the subiculum were
correlated with better verbal memory retrieval [12]. Another study on
healthy younger adults using high-field MRI with manual hippocampal
segmentation revealed that verbal memory performance [8] measured
by the Wechsler Memory Scale III [13] was correlated with larger vo-
lumes of the CA1, CA2-3 and CA4. Using a measure for auto-
biographical episodic memory [14] in healthy young adults, Palombo
et al. [15], found that volumes of the left CA2/3 and the bilateral
subiculum were associated with higher number of details generated
from an autobiographical interview. In case-control studies using the
California Verbal Learning Test (CVLT-II) [16] to assess verbal memory,
larger volumes of CA2-3 and CA4 were associated with better im-
mediate verbal recall, whereas CA1 volume correlated with better de-
layed verbal recall [17,18].
Early lesion studies indicated that verbal auditory memory is more
dependent on the left hippocampus compared to the right [19], which
have been supported in some more recent human volumetric studies
[15,20,21]. Furthermore, several studies in healthy adults have found
structural asymmetry with larger volumes of the right hippocampus
compared to the left [22–24]. This asymmetry has also been shown to
be associated with preserved memory functions in elderly persons,
where memory impaired subjects had no significant volume asymmetry
between the left and the right hippocampus [25]. The underlying me-
chanism for the structural asymmetry is unknown, but it may be related
to the functional specialization of the temporal lobes, where the left
side normally is more associated with verbal memory whereas the right
is associated with non-verbal memory functions [22,26]. Thus, a la-
teralization effect of verbal episodic memory on hippocampal subfield
volumes can be anticipated.
In the present study, we used the CVLT-II to assess verbal memory
functions in healthy adults of both sexes in a wide age-span to test
whether episodic verbal memory shows a lateralization effect in the
hippocampus. The CVLT II is extensively used in both clinical and sci-
entific settings [27], but there is limited data on the hippocampal
anatomical correlates of CVLT II performance in healthy volunteers.
Thus, data for structural correlates of the CVLT II is important for both
clinical and scientific purposes. Based on findings in previous studies
using similar methodology, we expected that different outcome mea-
sures of the CVLT-II had specific correlates of the hippocampal subfield
volumes. Specifically, we hypothesized that the left CA2-3 and CA4
volumes should be associated with the learning score and immediate
recall memory score, whereas the left CA1 and the subiculum should be
associated with delayed recall performance.
2. Methods
2.1. Participants
Forty-seven, right-handed volunteers (31 females) in the age range
22–71 (Mean=38.36, SD=20.16) years were recruited on the
campus of the University of Tromsø, Norway. The mean educational
level of the sample was 13.78 (SD=2.02) years (median= 14 years).
All participants signed an informed consent stating that they were
healthy and had no present or history of severe disease or injuries. The
study was approved by the Regional Committee for Research Ethics in
Medicine and Health Sciences (project 2012/1588) and was conducted
in accordance with the Declaration of Helsinki. The participants re-
ceived a gift card worth 300 Norwegian Kroner (approx. 37 EUR/47
USD) as compensation for their participation. Exclusion criteria were
previous concussions, traumatic brain injury, or other injuries or dis-
eases involving the central nervous system, including psychiatric con-
ditions. Patients on prescribed medications were excluded, with the
exception of oral contraceptives in women. Medical conditions, preg-
nancy, or body implants not compatible with participants’ safety in the
MR-scanner were also exclusion criteria.
2.2. Neuropsychological tests
Verbal episodic memory was measured by the Norwegian version of
the California Verbal Learning Test II (CVLT-II), standard version [16].
The CVLT-II measures verbal auditory learning, recall- and recognition
memory, and was administrated and scored according to the standar-
dized instructions. The learning trial gives a total score from five se-
parate recalls of a 16-item word list (List A) that is read aloud to the
examinee who is to repeat the words from the list in random order after
each reading. Thereafter, a second list (List B) is introduced as a dis-
tractor before the examinee is asked to recall as many items as possible
from List A. The correct items remembered from A after the distractor
list, comprises the Immediate recall trial. Then, the examiner asks the
participant to categorize the word list into four categories (i.e., furni-
ture, vegetables, clothes, and animals) to obtain a measure of Im-
mediate cued-recall abilities. Twenty minutes after the total learning
trial, the free and cued recall of List A are repeated, and comprise the
delayed recall trial and the delayed cued recall trial, respectively. At
last a recognition trial and a forced recognition trial is performed.
The results from the cued recall trials were not included in the
present data analyses due to high correlations with the free recall data
(r> 0.70) and the small sample size restricting the number of com-
parisons to be performed.
The raw scores from the CVLT-II total learning trial, immediate and
delayed recall trials and the recognition trials were converted to stan-
dard scores using published normative data that corrects for both age
and sex. Validity studies of the Norwegian version of the CVLT-II have
shown good fit between the Norwegian translation and American norms
[28].
Visual-spatial abilities and crystallized intelligence were assessed by
two subtests (Matrix Reasoning and Vocabulary) from the Norwegian
version of the Wechsler Abbreviated Scale of Intelligence (WASI) [29].
The Vocabulary subtest demands that the examinee gives overt ex-
planations of words with an increasing level of difficulty. The Norwe-
gian version of the WASI has shown acceptable fit to American nor-
mative data [30]. The Matrix reasoning is a non-verbal subtest
measuring visual-perceptual- and problem solving ability. WASI scores
are converted to standardized scores by normative data, correcting for
age, but not sex.
2.3. MRI acquisition
Subjects were scanned in a 1.5 T Phillips Intera MR scanner using an
8-channel head coil. The T1-weighted structural scans were 3D turbo
field echo scan with TR=1.825ms, TI= 855ms, TE= 4.0ms, flip
angle= 8°, and voxel resolution= 0.94× 0.94× 1.25 mm3. The MRI
scanning was performed within a month after cognitive testing for all
participants.
2.4. Volumetric MRI analysis
Hippocampal subfields were calculated by an automated segmen-
tation process [31] implemented in Freesurfer 6.0 (https://surfer.nmr.
mgh.harvard.edu/). FreeSurfer automatically labels each voxel of the
T1 MR-images to one of 40 predefined structures by using probabilistic
brain atlases [32–34]. In the present study, the volumetric data for the
hippocampal subfields, estimated total intracranial volume and total
left and right hippocampus volumes were used. See Fig. 1 for an ex-
ample of segmentation based on Freesurfer 6.0 from the present study.
The volumes used in the correlation analyses were adjusted for age, sex
and estimated total intracranial volume (eTIV). The adjustments were
performed by linear regressions where brain volumes were dependent
variables, and age, sex and eTIV were entered as predictors. The stan-
dardized residuals from the regressions were then saved and used for
the analyses. The adjusted volumes (residuals) for the left and the right
Cornu Ammonis (CA) CA1, CA2/3, CA4/Dentate Gyrus (DG),
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presubiculum, subiculum and the total volumes of the right and the left
hippocampus were correlated with performance on cognitive tests.
2.5. Statistical analyses
The distribution of the calculated residuals was not significantly
different from a normal distribution shown by the Shapiro-Wilk test,
and this was further confirmed by inspection of QeQ plots of the re-
siduals. Thus, parametric statistical testing was performed. Independent
samples t-test were used to test group-differences in unadjusted vo-
lumes. Paired samples t-tests were used to compare differences between
the left and the right hippocampal formations. Correlations between
hippocampal volumes and CVLT II subtests were performed with
Pearson correlations, and in order to adjust p-values for multiple testing
and reducing the probability of type I errors, p-values were adjusted
with the False Discovery Rate (FDR) procedure with q=0.05 [35,36].
After FDR adjustments performed with a script for SPSS (http://www-
01.ibm.com/support/docview.wss?uid=swg21476447) the level of
significance was p < .0044 for the correlational analyses between
cognitive performance and hippocampal subfields. Elsewhere, p-va-
lues< .05 were considered significant. To test whether correlations
were significantly different based on their z-score distribution, the
Fisher r-to-z transformation test was employed.
3. Results
3.1. Cognitive data
Descriptive data for CVLT II, WASI, and volumetric measures are
presented in Table 1. The sample means of the cognitive tests were
within one standard deviation from the normative means, however, the
results on the CVLT II showed that one abnormally low score (below 2
SD from the normative mean) from separate participants occurred on
all CVLT subtests. All participants performed within the statistical
normal range (T-score> 40) measured by the WASI tests, and the fre-
quency of abnormal scores was not deviant from other studies using
neuropsychological methodology [37]. There were no significant sex
differences in CVLT II adjusted scores (all t’s< 1.82), but females
performed better compared to males based on the unadjusted raw
scores on the recognition subtest (t (45)= 2.26, p= .03). No other
comparison between males and females performance on the CVLT II
reached significance.
3.2. Unadjusted volumetric data
Males had larger right hippocampus (t (45)= 2.15, p= .037) and
larger eTIV (t (45)= 5.07, p < .001), but there was no sex difference
in left hippocampal volume (t (45)= 1.17, p= .25). There were sig-
nificant differences in volumes between the left and the right hemi-
sphere on the hippocampal subfield measures shown by paired samples
t-tests (all t’s (46)< 5.01, all p’s< .001) with exception of the com-
parison left versus right subiculum (t (46)= 0.45, p= .65). The right
subfields were larger (p < .05) compared to the left subfields, with the
exception of the left presubiculum being larger than the right (t
(46)= 5.03, p < .001). All t-tests on the left versus right comparisons
of volumetric data are presented in Table 2. Univariate Pearson corre-
lations between the left hippocampus, the right hippocampus and total
hippocampal size and age and eTIV revealed that age had no significant
association with any of the volumetric data, but there was a non-sig-
nificant tendency to negative correlations between age and volumes.
eTIV was significantly associated with left hippocampal volume
(r= .49, p < .01), right hippocampal volume (r= .59, p < .001) and
total hippocampal volume (r= .55, p < .001).
Fig. 1. Example of segmentation of hippocampal subfields based on T1-weighted MRI. Voxel resolution= 0.94×0.94× 1.25 mm3.
Table 1
Descriptive statistics. SD= Standard deviation. WASI=Wechsler Abbreviated
Scale of Intelligence, CVLT=California Verbal Learning Test II.
eTIV=Estimated total intracranial volume. WASI and CVLT II Total learning
scores are shown in T-scores (normative mean= 50, SD=10), other CVLT II
scores are shown in Z-scores (normative mean= 0, SD=1). N=47, 31 fe-
males.
Variable Mean Median SD Minimum Maximum
Age at scanning 38.4 34 20.2 20 71
WASI Matrix reasoning 56.9 57 7.1 37 69
WASI Vocabulary 57.5 58 7.9 40 70
CVLT Total learning 53.4 53 10.3 24 69
CVLT Immediate recall .47 .50 .99 −2 2
CVLT Delayed recall .42 .50 .97 −2 1.5
CVLT Recognition −.01 0 .63 −2 1
eTIV, cm3 1572 1544 134 1370 1932
Left hippocampus, mm3 3428 3410 285 2875 4202
Right hippocampus, mm3 3511 3483 298 2937 4226
Whole hippocampus, mm3 6939 6966 575 5812 8428
CA1, mm3 1270 1265 119 1041 1558
CA2/3, mm3 426 424 45 335 552
CA4/DG, mm3 520 526 47 438 644
Subiculum, mm3 861 844 88 711 1093
Presubiculum, mm3 612 597 67 473 781
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3.3. Correlation analyses on data adjusted for age, sex and eTIV
The correlation analyses showed that there were no significant as-
sociations between the right hippocampal subfields residuals and the
CVLT II subtests. There were several significant correlations (p < .05)
between the CVLT II subtests and left hippocampal subfields residuals,
however when applying the FDR adjustments (p < .0044), only the
CA1, CA2/3 and the CA4 had significant associations with verbal
memory performance (Table 3 and Fig. 2). There were no significant
correlations between performance on the WASI and hippocampal
measures when adjusting p-values with the FDR procedure. The Fisher
r-to-z transformation tests showed that none of the significant correla-
tions between subfields in the left and CVLT II performance was sig-
nificantly different from the same correlations in the right subfields
when using the z-score as criterion. The z-scores of the difference
ranged from z=1.34, p= .09 to z= 0.99, p= .16 (one-tailed). The
correlations between the merged (left+ right) subfields and CVLT II
performance showed that larger volume of the CA1 was significantly
associated with better delayed recall performance. However, the whole
hippocampus, the CA2/3 and the CA4/DG had correlations with all
CVLT II measures with the exception of the recognition score, but the
significance of these correlations did not pass the FDR criterion (see
Table 3).
4. Discussion
In accordance with our hypothesis, the present results showed sig-
nificant associations between larger volumes of the left hippocampal
subfields (CA1, CA2/3, CA4/DG) corrected for age, sex and eTIV with
verbal learning and memory performance. Specifically, volume of the
CA1 correlated with delayed recall, whereas volume of the CA2/3 was
related to immediate and delayed recall, and volume of the CA4/DG
were significantly associated with learning, immediate and delayed
recall. Volumes of the right hippocampal subfields were not sig-
nificantly related to verbal learning or recall performance. This later-
alization effect in hippocampal subfields is not previously shown for
verbal memory tests that include list learning, which is the type of test
most commonly used for measuring verbal episodic memory [27]. Two
previous studies [20,21] found a similar effect of the whole left hip-
pocampus without separating the subfileds. Moreover, a recent study by
Palombo et al. [15], found that performance on the Autobiographical
Interview [38] correlated significantly with the left CA2/3 but not the
right CA2/3.
The analyses of structural volumes showed that the right CA1, CA2/
3 and the CA4/DG were larger compared the same structures in the left
hemisphere. The presubiculum was the only subfield in the left hip-
pocampus being larger than the subfields in the right hemisphere. This
is in line with several previous studies [22–24] on healthy volunteers
showing a structural asymmetry of hippocampal volumes. In patients
with Alzheimer’s disease, episodic memory deficits are more associated
with volumes of the left subfields compared to the right subfields [39],
and the structural asymmetry of the hippocampal volumes is absent. It
has been suggested that the left compared to the right hippocampus is
more affected by atrophy caused by vascular and neurodegenerative
processes in Alzheimer’s disease [40]. Thus, the episodic verbal
memory deficits in Alzheimer’s disease could to some extent be caused
by increased left hippocampus vulnerability compared to the right
hippocampus [41]. Taken together, several studies in both healthy
volunteers and patients suggest that the left hippocampus is more in-
volved in verbal episodic memory in healthy volunteers compared to
the right hippocampus.
Previous studies have suggested that CA2/3 and CA4/DG are
structures more related to encoding and learning than recall, whereas
the CA1 is an output structure mainly related to retrieval functions
[42–44]. The results from the present study support these suggestions,
except that volumes of the CA2/3 and the CA4/DG were related to
performance in the recall stage of verbal memory, and not solely as-
sociated with the learning phase. This is in line with a 7 T fMRI study
showing that the CA2/3 and CA4/DG are activated both during
learning and recall, however more in the learning phase [45]. In
comparison to Zammit et al [12], we did not find any correlation be-
tween volume of the left or right subiculum and verbal memory.
Zammit et al [12] used only data for the merged left and the right
subfields in their analyses in contrast to the present study.
The partially divergent findings on the relation between hippo-
campal morphometric data and verbal memory performance may be
due to several methodological differences between studies. Different
verbal memory tests have been employed across volumetric studies on
hippocampal subfields. The Free and Cued Selective Reminding Test
[12], The Autobiographical Interview [15] and the Wechsler Memory
Scale (WMS-IV) [8] have been used in healthy samples, whereas the
WMS-III [46], the CVLT [17,46] and the Brief Assessment of Cognition
in Schizophrenia [47] have been used in studies with mixed samples of
healthy controls and patients. Even if tests for episodic verbal memory
are highly correlated, the concordance is not perfect between tests
[48,49]. Hence, different tests designed for measuring episodic memory
might measure different aspects of the construct and may produce
variability in hippocampal correlates. In addition, Zammit et al [12]
Table 2







Hippocampus - whole mm3 3428 3511 −5.51 < .001
CA1 mm3 621 648 −5.44 < .001
CA2/3 mm3 201 224 −8.20 < .001
CA4/DG mm3 252 268 −6.77 < .001
Subiculum mm3 431 429 .45 .65
Presubiculum mm3 315 297 5.01 < .001
Table 3
Pearson correlations between CVLT-II subtests and volumes of hippocampal
subfields and hippocampus. Volumes are standardized residuals from linear
regressions in order to adjust for total intracranial volume, sex, and age.
L= Left, R=Right. * = p < .05 unadjusted, bold ** = p < .0044 FDR ad-
justed. CA=Cornu Ammonis, CVLT=California Verbal Learning Test II.















.27 .33* .32* .08
L CA1 .30* .30* .43** .17
L CA2/3 .34* .43** .41** .27
L CA4/DG .40** .42** .47** .15
L Subiculum .05 .19 .12 .01
L Presubiculum −.19 −.11 −.07 −.23
R hippocampus -
whole
.18 .27 .23 .02
R CA1 .24 .27 .28 .17
R CA2/3 .14 .29 .22 −.07
R CA4/DG .22 .32* .26 −.03
R Subiculum .01 .10 .09 −.05




.26 .31* .26 −.03
CA1 .28 .30 .40** .20
CA2/3 .25 .39* .33* .10
CA4/DG .33* .38* .39* .15
Subiculum .09 .14 .21 .11
Presubiculum −.15 −.16 −.11 .03
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employed FreeSurfer for automatic volumetric segmentation in healthy
volunteers, whereas Travis et al [8] and Palombo et al [15] used a
manual segmentation procedure. Different methods for estimating vo-
lume may produce small but measurable differences in estimates of
cerebral structures [50]. Additionally, the age span in studies on
healthy volunteers differ across studies, from participants below 35
years [8,15] to elderly with a mean age at approx. 79 years [12]. The
present study recruited volunteers in the age span 20 to 71 years, but
there were no significant linear association between unadjusted hip-
pocampal volumes and age. Previous studies have suggested that the
linear effect of age is small, but still significant with negative correla-
tions between age and volume in healthy cognitively preserved elderly
[51], even if the rate of age-releated athrophy is suggested to be low (≤
0.2% per year) [52]. On the other hand, age effects and brain
maturation do often show complex and non-linear patterns and other
statistical models than the linear approach might be better suited for
this purpose [53]. Furthermore, even if there were no significant as-
sociation between age and unadjusted hippocampal subfield volumes in
the present study, previous studies have found that structural changes
of the hippocampus during development may contribute to age-related
differences in episodic memory [54]. In healthy elderly, a positive re-
lationship between preserved memory functions and hippocampus vo-
lume is generally supported, even if some studies found no such asso-
ciation or a negative association, for an overview see Kaup et al. [9].
Females perform generally better on tests related to episodic
memory compared to males, and the CVLT II norms are adjusted for sex
[16]. Data from the present study did not show any sex difference on
adjusted CVLT II scores, but females performed better on the
Fig. 2. Scatterplots for correlations between CVLT II subtests and hippocampal volumes adjusted for age, sex and estimated intracranial volume (eTIV). r= Pearson
correlation coefficient.
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recognition subtest based on the unadjusted raw scores. The lack of sex
differences in the CVLT II raw score data may be attributed to the small
sample size and the educational level of the participants. Furthermore,
there are sex differences in hippocampal subfield volumes where fe-
males have larger volumes than males adjusted for intracranial volume,
but males and females display similar decrease of hippocampal volumes
with age [52]. In the present study, we adjusted for both the effects of
sex and age in the correlation analyses between CVLT performance and
volumetric data, and the results cannot inform about the impact of sex
and age on episodic memory.
The main limitations of the present study are the small sample size
and the large variability in age of the included participants. The Fisher
r-to-z transformation tests showed that the distributions based on the
correlations in the left and the right subfields did not differ sig-
nificantly, even if the FDR-adjusted p-value from the correlations were
significant. Furthermore, when using the FDR correction for controlling
familywise error rates, there is a risk of type-II errors when rejecting
correlations with p-values close to the FDR criterion. Hence, the gen-
eralizability of the findings is questionable and the results should be
regarded as preliminary findings that need conformation in larger
samples. Nonetheless, the significant results were in line with findings
from studies with related methodology [8,15,17,18]. Several associa-
tions between hippocampal subfields volumes and verbal memory were
close to significance, and a larger sample may have provided clearer
findings. The Freesurfer segmentation process implemented in earlier
versions (5.3 and earlier) of the software has received criticism for
providing inaccurate estimates that conflicts with structural findings in
anatomical studies [55]. In this study, we used Freesurfer 6.0 where the
accuracy and correspondence with anatomical studies has been im-
proved [31], and this version of Freesurfer has shown good test-retest
reproductibility estimates for hippocampal segmentation in studies
with large samples [56]. However, results based on 1mm segmentation
of internal subfields such as the CA4 should be interpreted with caution
and further validation of the software with higher resolution should be
performed to confirm the results. Thus, improvements in software and
increased field-strength of MR-images might produce more accurate
findings in future larger studies.
5. Conclusion
In summary, the present study showed that verbal learning, im-
mediate- and delayed recall measured by the CVLT II had significant
relations with separate subfields of the left hippocampus in healthy
adults in the ages between 22–71 years. Furthermore, there were no
significant associations between the right hippocampal subfields and
verbal memory performance suggesting that auditory verbal memory is
associated with volumetric lateralization effects in the hippocampus.
The present results should be replicated in larger samples, and should
be interpreted with caution due to the small sample size and large
variability in age of the included participants.
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